Title: LEGISLATIVE BILL 475
Official Title: LEGISLATIVE BILL 475
Number of Sections: 1
Source: versions - Introduced
Media Type: application/pdf
Strikethrough Detection: 37 sections found

================================================================================

Section 1:
LB475 LB475
2025 2025
LEGISLATURE OF NEBRASKA
ONE HUNDRED NINTH LEGISLATURE
FIRST SESSION
Introduced by Riepe, 12.
Read first time January 21, 2025
Committee: Judiciary
1 A BILL FOR AN ACT relating to Uniform controlled Substances Act; to amend
2 section 28-405, Revised Statutes Cumulative Supplement, 2024; to
3 classify tianeptine as a controlled substance; and to repeal the
4 original section.
5 Be it enacted by the people of the State of Nebraska,
-1-
LB475 LB475
2025 2025
1 Section 1. Section 28-405, Revised Statutes Cumulative Supplement,
2 2024, is amended to read:
3 28-405 The following are the schedules of controlled substances
4 referred to in the Uniform Controlled Substances Act, unless specifically
5 contained on the list of exempted products of the Drug Enforcement
6 Administration of the United States Department of Justice as the list
7 existed on January 31, 2022:
8 Schedule I
9 (a) Any of the following opiates, including their isomers, esters,
10 ethers, salts, and salts of isomers, esters, and ethers, unless
11 specifically excepted, whenever the existence of such isomers, esters,
12 ethers, and salts is possible within the specific chemical designation:
13 (1) Acetylmethadol;
14 (2) Allylprodine;
15 (3) Alphacetylmethadol, except levo-alphacetylmethadol which is also
16 known as levo-alpha-acetylmethadol, levomethadyl acetate, and LAAM;
17 (4) Alphameprodine;
18 (5) Alphamethadol;
19 (6) Benzethidine;
20 (7) Betacetylmethadol;
21 (8) Betameprodine;
22 (9) Betamethadol;
23 (10) Betaprodine;
24 (11) Clonitazene;
25 (12) Dextromoramide;
26 (13) Difenoxin;
27 (14) Diampromide;
28 (15) Diethylthiambutene;
29 (16) Dimenoxadol;
30 (17) Dimepheptanol;
31 (18) Dimethylthiambutene;
-2-
LB475 LB475
2025 2025
1 (19) Dioxaphetyl butyrate;
2 (20) Dipipanone;
3 (21) Ethylmethylthiambutene;
4 (22) Etonitazene;
5 (23) Etoxeridine;
6 (24) Furethidine;
7 (25) Hydroxypethidine;
8 (26) Ketobemidone;
9 (27) Levomoramide;
10 (28) Levophenacylmorphan;
11 (29) Morpheridine;
12 (30) Noracymethadol;
13 (31) Norlevorphanol;
14 (32) Normethadone;
15 (33) Norpipanone;
16 (34) Phenadoxone;
17 (35) Phenampromide;
18 (36) Phenomorphan;
19 (37) Phenoperidine;
20 (38) Piritramide;
21 (39) Proheptazine;
22 (40) Properidine;
23 (41) Propiram;
24 (42) Racemoramide;
25 (43) Trimeperidine;
26 (44) Alpha-methylfentanyl, N-(1-(alpha-methyl-beta-phenyl)ethyl-4-
27 piperidyl) propionanilide, 1-(1-methyl-2-phenylethyl)-4-(N-propanilido)
28 piperidine;
29 (45) Tilidine;
30 (46) 3-Methylfentanyl, N-(3-methyl-1-(2-phenylethyl)-4-piperidyl)-N-
31 phenylpropanamide, its optical and geometric isomers, salts, and salts of
-3-
LB475 LB475
2025 2025
1 isomers;
2 (47) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP), its optical
3 isomers, salts, and salts of isomers;
4 (48) PEPAP, 1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine, its
5 optical isomers, salts, and salts of isomers;
6 (49) Acetyl-alpha-methylfentanyl, N-(1-(1-methyl-2-phenethyl)-4-
7 piperidinyl)-N-phenylacetamide, its optical isomers, salts, and salts of
8 isomers;
9 (50) Alpha-methylthiofentanyl, N-(1-methyl-2-(2-thienyl)ethyl-4-
10 piperidinyl)-N-phenylpropanamide, its optical isomers, salts, and salts
11 of isomers;
12 (51) Benzylfentanyl, N-(1-benzyl-4-piperidyl)-N-phenylpropanamide,
13 its optical isomers, salts, and salts of isomers;
14 (52) Beta-hydroxyfentanyl, N-(1-(2-hydroxy-2-phenethyl)-4-
15 piperidinyl)-N-phenylpropanamide, its optical isomers, salts, and salts
16 of isomers;
17 (53) Beta-hydroxy-3-methylfentanyl, (other name: N-(1-(2-hydroxy-2-
18 phenethyl)-3-methyl-4-piperidinyl)-N-phenylpropanamide), its optical and
19 geometric isomers, salts, and salts of isomers;
20 (54) 3-methylthiofentanyl, N-(3-methyl-1-(2-thienyl)ethyl-4-
21 piperidinyl)-N-phenylpropanamide, its optical and geometric isomers,
22 salts, and salts of isomers;
23 (55) N-(1-(2-thienyl)methyl-4-piperidyl)-N-phenylpropanamide
24 (thenylfentanyl), its optical isomers, salts, and salts of isomers;
25 (56) Thiofentanyl, N-phenyl-N-(1-(2-thienyl)ethyl-4-piperidinyl)-
26 propanamide, its optical isomers, salts, and salts of isomers;
27 (57) Para-fluorofentanyl, N-(4-fluorophenyl)-N-(1-(2-phenethyl)-4-
28 piperidinyl)propanamide, its optical isomers, salts, and salts of
29 isomers;
30 (58) U-47700, 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-
31 methylbenzamide;
-4-
LB475 LB475
2025 2025
1 (59) 4-Fluoroisobutyryl Fentanyl;
2 (60) Acetyl Fentanyl;
3 (61) Acyrloylfentanyl;
4 (62) AH-7921; 3, 4-dichloro-N-[(1-dimethylamino) cyclohexylmethyl]
5 benzamide;
6 (63) Butyryl fentanyl;
7 (64) Cyclopentyl fentanyl;
8 (65) Cyclopropyl fentanyl;
9 (66) Furanyl fentanyl;
10 (67) Isobutyryl fentanyl;
11 (68) Isotonitazene;
12 (69) Methoxyacetyl fentanyl;
13 (70) MT-45; 1-cyclohexyl-4-(1,2-diphenylethyl) piperazine;
14 (71) Tetrahydrofuranyl fentanyl;
15 (72) 2-fluorofentanyl; N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-
16 yl) propionamide;
17 (73) Ocfentanil;
18 (74) Ortho-Fluorofentanyl;
19 (75) Para-chloroisobutyryl fentanyl;
20 (76) Para-Fluorobutyryl Fentanyl;
21 (77) Valeryl fentanyl;
22 (78) Phenyl Fentanyl;
23 (79) Para-Methylfentanyl;
24 (80) Thiofuranyl Fentanyl;
25 (81) Beta-methyl Fentanyl;
26 (82) Beta'-Phenyl Fentanyl;
27 (83) Crotonyl Fentanyl;
28 (84) 2'-Fluoro Ortho-Fluorofentanyl;
29 (85) 4'-Methyl Acetyl Fentanyl;
30 (86) Ortho-Fluorobutyryl Fentanyl;
31 (87) Ortho-Methyl Acetylfentanyl;
-5-
LB475 LB475
2025 2025
1 (88) Ortho-Methyl Methoxyacetyl Fentanyl;
2 (89) Ortho-Fluoroacryl Fentanyl;
3 (90) Fentanyl Carbamate;
4 (91) Ortho-Fluoroisobutyryl Fentanyl;
5 (92) Para-Fluoro Furanyl Fentanyl;
6 (93) Para-Methoxybutyryl Fentanyl;
7 (94) Brorphine (other name: 1-(1-(1-(4-bromophenyl) ethyl)
8 piperidin-4-yl-1,3-dihydro-2H-benzo[D]imidazole-2-one); and
9 (95) Fentanyl-related substances, their isomers, esters, ethers,
10 salts and salts of isomers, esters, and ethers. Unless specifically
11 excepted, listed in another schedule, or specifically named in this
12 schedule, this includes any substance that is structurally related to
13 fentanyl by one or more of the following modifications:
14 (A) Replacement of the phenyl portion of the phenethyl group by any
15 monocycle, whether or not further substituted in or on the monocycle;
16 (B) Substitution in or on the phenethyl group with alkyl, alkenyl,
17 alkoxyl, hydroxyl, halo, haloalkyl, amino, or nitro groups;
18 (C) Substitution in or on the piperidine ring with alkyl, alkenyl,
19 alkoxyl, ester, ether, hydroxyl, halo, haloalkyl, amino, or nitro groups;
20 (D) Replacement of the aniline ring with any aromatic monocycle
21 whether or not further substituted in or on the aromatic monocycle; or
22 (E) Replacement of the N-propionyl group by another acyl group.
23 (b) Any of the following opium derivatives, their salts, isomers,
24 and salts of isomers, unless specifically excepted, whenever the
25 existence of such salts, isomers, and salts of isomers is possible within
26 the specific chemical designation:
27 (1) Acetorphine;
28 (2) Acetyldihydrocodeine;
29 (3) Benzylmorphine;
30 (4) Codeine methylbromide;
31 (5) Codeine-N-Oxide;
-6-
LB475 LB475
2025 2025
1 (6) Cyprenorphine;
2 (7) Desomorphine;
3 (8) Dihydromorphine;
4 (9) Drotebanol;
5 (10) Etorphine, except hydrochloride salt;
6 (11) Heroin;
7 (12) Hydromorphinol;
8 (13) Methyldesorphine;
9 (14) Methyldihydromorphine;
10 (15) Morphine methylbromide;
11 (16) Morphine methylsulfonate;
12 (17) Morphine-N-Oxide;
13 (18) Myrophine;
14 (19) Nicocodeine;
15 (20) Nicomorphine;
16 (21) Normorphine;
17 (22) Pholcodine; and
18 (23) Thebacon.
19 (c) Any material, compound, mixture, or preparation which contains
20 any quantity of the following hallucinogenic substances, their salts,
21 isomers, and salts of isomers, unless specifically excepted, whenever the
22 existence of such salts, isomers, and salts of isomers is possible within
23 the specific chemical designation, and, for purposes of this subdivision
24 only, isomer shall include the optical, position, and geometric isomers:
25 (1) Bufotenine. Trade and other names shall include, but are not
26 limited to: 3-(beta-Dimethylaminoethyl)-5-hydroxyindole; 3-(2-
27 dimethylaminoethyl)-5-indolol; N,N-dimethylserotonin; 5-hydroxy-N,N-
28 dimethyltryptamine; and mappine;
29 (2) 4-bromo-2,5-dimethoxyamphetamine. Trade and other names shall
30 include, but are not limited to: 4-bromo-2,5-dimethoxy-alpha-
31 methylphenethylamine; and 4-bromo-2,5-DMA;
-7-
LB475 LB475
2025 2025
1 (3) 4-methoxyamphetamine. Trade and other names shall include, but
2 are not limited to: 4-methoxy-alpha-methylphenethylamine; and
3 paramethoxyamphetamine, PMA;
4 (4) 4-methyl-2,5-dimethoxyamphetamine. Trade and other names shall
5 include, but are not limited to: 4-methyl-2,5-dimethoxy-alpha-
6 methylphenethylamine; DOM; and STP;
7 (5) Para-methoxymethamphetamine. Trade and other names shall
8 include, but are not limited to: 1-(4-Methoxyphenyl)-N-methylpropan-2-
9 amine, PMMA, and 4-MMA;
10 (6) Ibogaine. Trade and other names shall include, but are not
11 limited to: 7-Ethyl-6,6beta,7,8,9,10,12,13-octahydro-2-methoxy-6,9-
12 methano-5H-pyrido (1',2':1,2) azepino (5,4-b) indole; and Tabernanthe
13 iboga;
14 (7) Lysergic acid diethylamide;
15 (8) Marijuana;
16 (9) Mescaline;
17 (10) Methoxetamine (MXE);
18 (11) Peyote. Peyote shall mean all parts of the plant presently
19 classified botanically as Lophophora williamsii Lemaire, whether growing
20 or not, the seeds thereof, any extract from any part of such plant, and
21 every compound, manufacture, salts, derivative, mixture, or preparation
22 of such plant or its seeds or extracts;
23 (12) Psilocybin;
24 (13) Psilocyn;
25 (14) Tetrahydrocannabinols, including, but not limited to, synthetic
26 equivalents of the substances contained in the plant or in the resinous
27 extractives of cannabis, sp. or synthetic substances, derivatives, and
28 their isomers with similar chemical structure and pharmacological
29 activity such as the following: Delta 1 cis or trans tetrahydrocannabinol
30 and their optical isomers, excluding dronabinol in a drug product
31 approved by the federal Food and Drug Administration; Delta 6 cis or
-8-
LB475 LB475
2025 2025
1 trans tetrahydrocannabinol and their optical isomers; and Delta 3,4 cis
2 or trans tetrahydrocannabinol and its optical isomers. Since nomenclature
3 of these substances is not internationally standardized, compounds of
4 these structures shall be included regardless of the numerical
5 designation of atomic positions covered. Tetrahydrocannabinols does not
6 include cannabidiol contained in a drug product approved by the federal
7 Food and Drug Administration;
8 (15) N-ethyl-3-piperidyl benzilate;
9 (16) N-methyl-3-piperidyl benzilate;
10 (17) Thiophene analog of phencyclidine. Trade and other names shall
11 include, but are not limited to: 1-(1-(2-thienyl)-cyclohexyl)-piperidine;
12 2-thienyl analog of phencyclidine; TPCP; and TCP;
13 (18) Hashish or concentrated cannabis;
14 (19) Parahexyl. Trade and other names shall include, but are not
15 limited to: 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
16 dibenzo(b,d)pyran; and Synhexyl;
17 (20) Ethylamine analog of phencyclidine. Trade and other names shall
18 include, but are not limited to: N-ethyl-1-phenylcyclohexylamine; (1-
19 phenylcyclohexyl)ethylamine; N-(1-phenylcyclohexyl)ethylamine;
20 cyclohexamine; and PCE;
21 (21) Pyrrolidine analog of phencyclidine. Trade and other names
22 shall include, but are not limited to: 1-(1-phenylcyclohexyl)-
23 pyrrolidine; PCPy; and PHP;
24 (22) Alpha-ethyltryptamine. Some trade or other names: etryptamine;
25 Monase; alpha-ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl) indole;
26 alpha-ET; and AET;
27 (23) 2,5-dimethoxy-4-ethylamphet-amine; and DOET;
28 (24) 1-(1-(2-thienyl)cyclohexyl)pyrrolidine; and TCPy;
29 (25) Alpha-methyltryptamine, which is also known as AMT;
30 (26) Salvia divinorum or Salvinorin A. Salvia divinorum or
31 Salvinorin A includes all parts of the plant presently classified
-9-
LB475 LB475
2025 2025
1 botanically as Salvia divinorum, whether growing or not, the seeds
2 thereof, any extract from any part of such plant, and every compound,
3 manufacture, derivative, mixture, or preparation of such plant, its
4 seeds, or its extracts, including salts, isomers, and salts of isomers
5 whenever the existence of such salts, isomers, and salts of isomers is
6 possible within the specific chemical designation;
7 (27) Any material, compound, mixture, or preparation containing any
8 quantity of synthetically produced cannabinoids as listed in subdivisions
9 (A) through (L) of this subdivision, including their salts, isomers,
10 salts of isomers, and nitrogen, oxygen, or sulfur-heterocyclic analogs,
11 unless specifically excepted elsewhere in this section. Since
12 nomenclature of these synthetically produced cannabinoids is not
13 internationally standardized and may continually evolve, these structures
14 or compounds of these structures shall be included under this
15 subdivision, regardless of their specific numerical designation of atomic
16 positions covered, so long as it can be determined through a recognized
17 method of scientific testing or analysis that the substance contains
18 properties that fit within one or more of the following categories:
19 (A) Tetrahydrocannabinols: Meaning tetrahydrocannabinols naturally
20 contained in a plant of the genus cannabis (cannabis plant), as well as
21 synthetic equivalents of the substances contained in the plant, or in the
22 resinous extractives of cannabis, sp. and/or synthetic substances,
23 derivatives, and their isomers with similar chemical structure and
24 pharmacological activity such as the following: Delta 1 cis or trans
25 tetrahydrocannabinol, and their optical isomers; Delta 6 cis or trans
26 tetrahydrocannabinol, and their optical isomers; Delta 3,4 cis or trans
27 tetrahydrocannabinol, and its optical isomers. This subdivision does not
28 include cannabidiol contained in a drug product approved by the federal
29 Food and Drug Administration;
30 (B) Naphthoylindoles: Any compound containing a 3-(1-
31 naphthoyl)indole structure with substitution at the nitrogen atom of the
-10-
LB475 LB475
2025 2025
1 indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
2 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
3 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
4 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
5 tetrahydropyranylmethyl group, whether or not further substituted in or
6 on any of the listed ring systems to any extent;
7 (C) Naphthylmethylindoles: Any compound containing a 1 H-indol-3-
8 yl-(1-naphthyl)methane structure with substitution at the nitrogen atom
9 of the indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
10 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
11 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
12 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
13 tetrahydropyranylmethyl group, whether or not further substituted in or
14 on any of the listed ring systems to any extent;
15 (D) Naphthoylpyrroles: Any compound containing a 3-(1-
16 naphthoyl)pyrrole structure with substitution at the nitrogen atom of the
17 pyrrole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
18 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
19 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
20 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
21 tetrahydropyranylmethyl group, whether or not further substituted in or
22 on any of the listed ring systems to any extent;
23 (E) Naphthylideneindenes: Any compound containing a
24 naphthylideneindene structure with substitution at the 3-position of the
25 indene ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
26 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
27 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
28 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
29 tetrahydropyranylmethyl group, whether or not further substituted in or
30 on any of the listed ring systems to any extent;
31 (F) Phenylacetylindoles: Any compound containing a 3-
-11-
LB475 LB475
2025 2025
1 phenylacetylindole structure with substitution at the nitrogen atom of
2 the indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
3 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
4 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
5 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
6 tetrahydropyranylmethyl group, whether or not further substituted in or
7 on any of the listed ring systems to any extent;
8 (G) Cyclohexylphenols: Any compound containing a 2-(3-
9 hydroxycyclohexyl)phenol structure with substitution at the 5-position of
10 the phenolic ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
11 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
12 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
13 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
14 tetrahydropyranylmethyl group, whether or not substituted in or on any of
15 the listed ring systems to any extent;
16 (H) Benzoylindoles: Any compound containing a 3-(benzoyl)indole
17 structure with substitution at the nitrogen atom of the indole ring by an
18 alkyl, haloalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl,
19 cycloalkylethyl, 2-(4-morpholinyl)ethyl group, cyanoalkyl, 1-(N-methyl-2-
20 piperidinyl)methyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
21 morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not
22 further substituted in or on any of the listed ring systems to any
23 extent;
24 (I) Adamantoylindoles: Any compound containing a 3-adamantoylindole
25 structure with substitution at the nitrogen atom of the indole ring by an
26 alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl, benzyl,
27 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl,
28 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
29 morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not
30 further substituted in or on any of the listed ring systems to any
31 extent;
-12-
LB475 LB475
2025 2025
1 (J) Tetramethylcyclopropanoylindoles: Any compound containing a 3-
2 tetramethylcyclopropanoylindole structure with substitution at the
3 nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl,
4 alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-
5 methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
6 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
7 tetrahydropyranylmethyl group, whether or not further substituted in or
8 on any of the listed ring systems to any extent;
9 (K) Indole carboxamides: Any compound containing a 1-indole-3-
10 carboxamide structure with substitution at the nitrogen atom of the
11 indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl,
12 benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-
13 piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
14 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
15 tetrahydropyranylmethyl group, substitution at the carboxamide group by
16 an alkyl, methoxy, benzyl, propionaldehyde, adamantyl, 1-naphthyl,
17 phenyl, aminooxoalkyl group, or quinolinyl group, whether or not further
18 substituted in or on any of the listed ring systems to any extent or to
19 the adamantyl, 1-mapthyl, phenyl, aminooxoalkyl, benzyl, or
20 propionaldehyde groups to any extent;
21 (L) Indole carboxylates: Any compound containing a 1-indole-3-
22 carboxylate structure with substitution at the nitrogen atom of the
23 indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl,
24 benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-
25 piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
26 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
27 tetrahydropyranylmethyl group, substitution at the carboxylate group by
28 an alkyl, methoxy, benzyl, propionaldehyde, adamantyl, 1-naphthyl,
29 phenyl, aminooxoalkyl group, or quinolinyl group, whether or not further
30 substituted in or on any of the listed ring systems to any extent or to
31 the adamantyl, 1-mapthyl, phenyl, aminooxoalkyl, benzyl, or
-13-
LB475 LB475
2025 2025
1 propionaldehyde groups to any extent; and
2 (M) Any nonnaturally occurring substance, chemical compound,
3 mixture, or preparation, not specifically listed elsewhere in these
4 schedules and which is not approved for human consumption by the federal
5 Food and Drug Administration, containing or constituting a cannabinoid
6 receptor agonist as defined in section 28-401;
7 (28) Zipeprol 1-methoxy-3-[4-(2-methoxy-2-phenylethyl)piperazin-1-
8 yl]-1-phenylpropan-2-ol, including its isomers, esters, ethers, salts,
9 and salts of isomers, esters, and ethers, whenever the existence of such
10 isomers, esters, ethers, and salts is possible within the specific
11 chemical designation;
12 (29) Any material, compound, mixture, or preparation containing any
13 quantity of a substituted phenethylamine as listed in subdivisions (A)
14 through (C) of this subdivision, unless specifically excepted, listed in
15 another schedule, or specifically named in this schedule, that is
16 structurally derived from phenylethan-2-amine by substitution on the
17 phenyl ring with a fused methylenedioxy ring, fused furan ring, or a
18 fused tetrahydrofuran ring; by substitution with two alkoxy groups; by
19 substitution with one alkoxy and either one fused furan, tetrahydrofuran,
20 or tetrahydropyran ring system; or by substitution with two fused ring
21 systems from any combination of the furan, tetrahydrofuran, or
22 tetrahydropyran ring systems, whether or not the compound is further
23 modified in any of the following ways:
24 (A) Substitution of the phenyl ring by any halo, hydroxyl, alkyl,
25 trifluoromethyl, alkoxy, or alkylthio groups; (B) substitution at the 2-
26 position by any alkyl groups; or (C) substitution at the 2-amino nitrogen
27 atom with alkyl, dialkyl, benzyl, hydroxybenzyl, or methoxybenzyl groups,
28 and including, but not limited to:
29 (i) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine, which is also known
30 as 2C-C or 2,5-Dimethoxy-4-chlorophenethylamine;
31 (ii) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine, which is also known
-14-
LB475 LB475
2025 2025
1 as 2C-D or 2,5-Dimethoxy-4-methylphenethylamine;
2 (iii) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine, which is also known
3 as 2C-E or 2,5-Dimethoxy-4-ethylphenethylamine;
4 (iv) 2-(2,5-Dimethoxyphenyl)ethanamine, which is also known as 2C-H
5 or 2,5-Dimethoxyphenethylamine;
6 (v) 2-(4-lodo-2,5-dimethoxyphenyl)ethanamine, which is also known as
7 2C-I or 2,5-Dimethoxy-4-iodophenethylamine;
8 (vi) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine, which is also known
9 as 2C-N or 2,5-Dimethoxy-4-nitrophenethylamine;
10 (vii) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine, which is also
11 known as 2C-P or 2,5-Dimethoxy-4-propylphenethylamine;
12 (viii) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine, which is
13 also known as 2C-T-2 or 2,5-Dimethoxy-4-ethylthiophenethylamine;
14 (ix) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine, which is
15 also known as 2C-T-4 or 2,5-Dimethoxy-4-isopropylthiophenethylamine;
16 (x) 2-(4-bromo-2,5-dimethoxyphenyl)ethanamine, which is also known
17 as 2C-B or 2,5-Dimethoxy-4-bromophenethylamine;
18 (xi) 2-(2,5-dimethoxy-4-(methylthio)phenyl)ethanamine, which is also
19 known as 2C-T or 4-methylthio-2,5-dimethoxyphenethylamine;
20 (xii) 1-(2,5-dimethoxy-4-iodophenyl)-propan-2-amine, which is also
21 known as DOI or 2,5-Dimethoxy-4-iodoamphetamine;
22 (xiii) 1-(4-Bromo-2,5-dimethoxyphenyl)-2-aminopropane, which is also
23 known as DOB or 2,5-Dimethoxy-4-bromoamphetamine;
24 (xiv) 1-(4-chloro-2,5-dimethoxy-phenyl)propan-2-amine, which is also
25 known as DOC or 2,5-Dimethoxy-4-chloroamphetamine;
26 (xv) 2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-
27 methoxyphenyl)methyl]ethanamine, which is also known as 2C-B-NBOMe; 25B-
28 NBOMe or 2,5-Dimethoxy-4-bromo-N-(2-methoxybenzyl)phenethylamine;
29 (xvi) 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-
30 methoxyphenyl)methyl]ethanamine, which is also known as 2C-I-NBOMe; 25I-
31 NBOMe or 2,5-Dimethoxy-4-iodo-N-(2-methoxybenzyl)phenethylamine;
-15-
LB475 LB475
2025 2025
1 (xvii) N-(2-Methoxybenzyl)-2-(3,4,5-trimethoxyphenyl)ethanamine,
2 which is also known as Mescaline-NBOMe or 3,4,5-trimethoxy-N-(2-
3 methoxybenzyl)phenethylamine;
4 (xviii) 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-
5 methoxyphenyl)methyl]ethanamine, which is also known as 2C-C-NBOMe; or
6 25C-NBOMe or 2,5-Dimethoxy-4-chloro-N-(2-methoxybenzyl)phenethylamine;
7 (xix) 2-(7-Bromo-5-methoxy-2,3-dihydro-1-benzofuran-4-yl)ethanamine,
8 which is also known as 2CB-5-hemiFLY;
9 (xx) 2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4-
10 yl)ethanamine, which is also known as 2C-B-FLY;
11 (xxi) 2-(10-Bromo-2,3,4,7,8,9-hexahydropyrano[2,3-g]chromen-5-
12 yl)ethanamine, which is also known as 2C-B-butterFLY;
13 (xxii) N-(2-Methoxybenzyl)-1-(8-bromo-2,3,6,7- tetrahydrobenzo[1,2-
14 b:4,5-b']difuran-4-yl)-2-aminoethane, which is also known as 2C-B-FLY-
15 NBOMe;
16 (xxiii) 1-(4-Bromofuro[2,3-f][1]benzofuran-8-yl)propan-2-amine,
17 which is also known as bromo-benzodifuranylisopropylamine or bromo-
18 dragonFLY;
19 (xxiv) N-(2-Hydroxybenzyl)-4-iodo-2,5-dimethoxyphenethylamine, which
20 is also known as 2C-INBOH or 25I-NBOH;
21 (xxv) 5-(2-Aminopropyl)benzofuran, which is also known as 5-APB;
22 (xxvi) 6-(2-Aminopropyl)benzofuran, which is also known as 6-APB;
23 (xxvii) 5-(2-Aminopropyl)-2,3-dihydrobenzofuran, which is also known
24 as 5-APDB;
25 (xxviii) 6-(2-Aminopropyl)-2,3-dihydrobenzofuran, which is also
26 known as 6-APDB;
27 (xxix) 2,5-dimethoxy-amphetamine, which is also known as 2, 5-
28 dimethoxy-a-methylphenethylamine; 2, 5-DMA;
29 (xxx) 2,5-dimethoxy-4-ethylamphetamine, which is also known as DOET;
30 (xxxi) 2,5-dimethoxy-4-(n)-propylthiophenethylamine, which is also
31 known as 2C-T-7;
-16-
LB475 LB475
2025 2025
1 (xxxii) 5-methoxy-3,4-methylenedioxy-amphetamine;
2 (xxxiii) 4-methyl-2,5-dimethoxy-amphetamine, which is also known as
3 4-methyl-2,5-dimethoxy-amethylphenethylamine; DOM and STP;
4 (xxxiv) 3,4-methylenedioxy amphetamine, which is also known as MDA;
5 (xxxv) 3,4-methylenedioxymethamphetamine, which is also known as
6 MDMA;
7 (xxxvi) 3,4-methylenedioxy-N-ethylamphetamine, which is also known
8 as N-ethyl-alpha-methyl-3,4(methylenedioxy)phenethylamine, MDE, MDEA;
9 (xxxvii) 3,4,5-trimethoxy amphetamine; and
10 (xxxviii) n-hydroxy-3, 4-Methylenedioxy-N-Hydroxyamphetamine, which
11 is also known as N-hydroxyMDA;
12 (30) Any material, compound, mixture, or preparation containing any
13 quantity of a substituted tryptamine unless specifically excepted, listed
14 in another schedule, or specifically named in this schedule, that is
15 structurally derived from 2-(1H-indol-3-yl)ethanamine, which is also
16 known as tryptamine, by mono- or di-substitution of the amine nitrogen
17 with alkyl or alkenyl groups or by inclusion of the amino nitrogen atom
18 in a cyclic structure whether or not the compound is further substituted
19 at the alpha position with an alkyl group or whether or not further
20 substituted on the indole ring to any extent with any alkyl, alkoxy,
21 halo, hydroxyl, or acetoxy groups, and including, but not limited to:
22 (A) 5-methoxy-N,N-diallyltryptamine, which is also known as 5-MeO-
23 DALT;
24 (B) 4-acetoxy-N,N-dimethyltryptamine, which is also known as 4-AcO-
25 DMT or OAcetylpsilocin;
26 (C) 4-hydroxy-N-methyl-N-ethyltryptamine, which is also known as 4-
27 HO-MET;
28 (D) 4-hydroxy-N,N-diisopropyltryptamine, which is also known as 4-
29 HO-DIPT;
30 (E) 5-methoxy-N-methyl-N-isopropyltryptamine, which is also known as
31 5-MeOMiPT;
-17-
LB475 LB475
2025 2025
1 (F) 5-Methoxy-N,N-Dimethyltryptamine, which is also known as 5-MeO-
2 DMT;
3 (G) 5-methoxy-N,N-diisopropyltryptamine, which is also known as 5-
4 MeO-DiPT;
5 (H) Diethyltryptamine, which is also known as N,N-Diethyltryptamine,
6 DET; and
7 (I) Dimethyltryptamine, which is also known as DMT; and
8 (31)(A) Any substance containing any quantity of the following
9 materials, compounds, mixtures, or structures:
10 (i) 3,4-methylenedioxymethcathinone, or bk-MDMA, or methylone;
11 (ii) 3,4-methylenedioxypyrovalerone, or MDPV;
12 (iii) 4-methylmethcathinone, or 4-MMC, or mephedrone;
13 (iv) 4-methoxymethcathinone, or bk-PMMA, or PMMC, or methedrone;
14 (v) Fluoromethcathinone, or FMC;
15 (vi) Naphthylpyrovalerone, or naphyrone; or
16 (vii) Beta-keto-N-methylbenzodioxolylpropylamine or bk-MBDB or
17 butylone; or
18 (B) Unless listed in another schedule, any substance which contains
19 any quantity of any material, compound, mixture, or structure, other than
20 bupropion, that is structurally derived by any means from 2-
21 aminopropan-1-one by substitution at the 1-position with either phenyl,
22 naphthyl, or thiophene ring systems, whether or not the compound is
23 further modified in any of the following ways:
24 (i) Substitution in the ring system to any extent with alkyl,
25 alkoxy, alkylenedioxy, haloalkyl, hydroxyl, or halide substituents,
26 whether or not further substituted in the ring system by one or more
27 other univalent substituents;
28 (ii) Substitution at the 3-position with an acyclic alkyl
29 substituent; or
30 (iii) Substitution at the 2-amino nitrogen atom with alkyl or
31 dialkyl groups, or by inclusion of the 2-amino nitrogen atom in a cyclic
-18-
LB475 LB475
2025 2025
1 structure.
2 (d) Unless specifically excepted or unless listed in another
3 schedule, any material, compound, mixture, or preparation which contains
4 any quantity of the following substances having a depressant effect on
5 the central nervous system, including its salts, isomers, and salts of
6 isomers whenever the existence of such salts, isomers, and salts of
7 isomers is possible within the specific chemical designation:
8 (1) Amineptine 7-[(10,11-dihydro-5H-dibenzo[a,d]-cyclohepten-5-
9 yl)amino]heptanoic acid, including its salts, isomers, and salts of
10 isomers;
11 (2) Mecloqualone;
12 (3) Methaqualone; and
13 (4) Gamma-Hydroxybutyric Acid. Some other names include: GHB; Gamma-
14 hydroxybutyrate; 4-Hydroxybutyrate; 4-Hydroxybutanoic Acid; Sodium
15 Oxybate; and Sodium Oxybutyrate.
16 (e) Unless specifically excepted or unless listed in another
17 schedule, any material, compound, mixture, or preparation which contains
18 any quantity of the following substances having a stimulant effect on the
19 central nervous system, including its salts, isomers, and salts of
20 isomers:
21 (1) Fenethylline;
22 (2) N-ethylamphetamine;
23 (3) Aminorex; aminoxaphen; 2-amino-5-phenyl-2-oxazoline; or 4,5-
24 dihydro-5-phenyl-2-oxazolamine;
25 (4) Cathinone; 2-amino-1-phenyl-1-propanone; alpha-
26 aminopropiophenone; 2-aminopropiophenone; and norephedrone;
27 (5) Methcathinone, its salts, optical isomers, and salts of optical
28 isomers. Some other names: 2-(methylamino)-propiophenone; alpha-
29 (methylamino)propiophenone; 2-(methylamino)-1-phenylpropan-1-one; alpha-
30 N-methylaminopropiophenone; methylcathinone; monomethylpropion;
31 ephedrone; N-methylcathinone; AL-464; AL-422; AL-463; UR1432; and 4-MEC;
-19-
LB475 LB475
2025 2025
1 (6) (+/-)cis-4-methylaminorex; and (+/-)cis-4,5-dihydro-4-methyl-5-
2 phenyl-2-oxazolamine;
3 (7) N,N-dimethylamphetamine; N,N-alpha-trimethyl-benzeneethanamine;
4 and N,N-alpha-trimethylphenethylamine;
5 (8) Benzylpiperazine, 1-benzylpiperazine;
6 (9) 4,4'-dimethylaminorex (other names: 4,4'-DMAR, 4,5-dihydro-4-
7 methyl-5-(4-methylphenyl)-2-oxazolamine); and
8 (10) N-phenyl-N' -(3-(1- phenylpropan-2-yl)-1,2,3-oxadiazol-3-
9 ium-5-yl)carbamimidate), including its salts, isomers, and salts of
10 isomers.
11 (f) Any controlled substance analogue to the extent intended for
12 human consumption.
13 Schedule II
14 (a) Any of the following substances except those narcotic drugs
15 listed in other schedules whether produced directly or indirectly by
16 extraction from substances of vegetable origin, independently by means of
17 chemical synthesis, or by combination of extraction and chemical
18 synthesis:
19 (1) Opium and opiate, and any salt, compound, derivative, or
20 preparation of opium or opiate, excluding apomorphine, buprenorphine,
21 thebaine-derived butorphanol, dextrorphan, nalbuphine, nalmefene,
22 naloxone, and naltrexone and their salts, but including the following:
23 (A) Raw opium;
24 (B) Opium extracts;
25 (C) Opium fluid;
26 (D) Powdered opium;
27 (E) Granulated opium;
28 (F) Tincture of opium;
29 (G) Codeine;
30 (H) Ethylmorphine;
31 (I) Etorphine hydrochloride;
-20-
LB475 LB475
2025 2025
1 (J) Hydrocodone;
2 (K) Hydromorphone;
3 (L) Metopon;
4 (M) Morphine;
5 (N) Oxycodone;
6 (O) Oxymorphone;
7 (P) Oripavine;
8 (Q) Thebaine; and
9 (R) Dihydroetorphine;
10 (2) Any salt, compound, derivative, or preparation thereof which is
11 chemically equivalent to or identical with any of the substances referred
12 to in subdivision (1) of this subdivision, except that these substances
13 shall not include the isoquinoline alkaloids of opium;
14 (3) Opium poppy and poppy straw;
15 (4) Coca leaves and any salt, compound, derivative, or preparation
16 of coca leaves, and any salt, compound, derivative, or preparation
17 thereof which is chemically equivalent to or identical with any of these
18 substances, including cocaine or ecgonine and its salts, optical isomers,
19 and salts of optical isomers, except that the substances shall not
20 include decocainized coca leaves or extractions which do not contain
21 cocaine or ecgonine; and
22 (5) Concentrate of poppy straw, the crude extract of poppy straw in
23 either liquid, solid, or powder form which contains the phenanthrene
24 alkaloids of the opium poppy.
25 (b) Unless specifically excepted or unless in another schedule any
26 of the following opiates, including their isomers, esters, ethers, salts,
27 and salts of their isomers, esters, and ethers whenever the existence of
28 such isomers, esters, ethers, and salts is possible within the specific
29 chemical designation, dextrorphan excepted:
30 (1) Alphaprodine;
31 (2) Anileridine;
-21-
LB475 LB475
2025 2025
1 (3) Bezitramide;
2 (4) Diphenoxylate;
3 (5) Fentanyl;
4 (6) Isomethadone;
5 (7) Levomethorphan;
6 (8) Levorphanol;
7 (9) Metazocine;
8 (10) Methadone;
9 (11) Methadone-intermediate, 4-cyano-2-dimethylamino-4,4-diphenyl
10 butane;
11 (12) Moramide-intermediate, 2-methyl-3-morpholino-1,1-
12 diphenylpropane-carboxylic acid;
13 (13) Norfentanyl (N-phenyl-N-piperidin-4-yl) propionamide;
14 (14) Oliceridine;
15 (15) Pethidine or meperidine;
16 (16) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;
17 (17) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-
18 carboxylate;
19 (18) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-
20 carboxylic acid;
21 (19) Phenazocine;
22 (20) Piminodine;
23 (21) Racemethorphan;
24 (22) Racemorphan;
25 (23) Dihydrocodeine;
26 (24) Bulk Propoxyphene in nondosage forms;
27 (25) Sufentanil;
28 (26) Alfentanil;
29 (27) Levo-alphacetylmethadol which is also known as levo-alpha-
30 acetylmethadol, levomethadyl acetate, and LAAM;
31 (28) Carfentanil;
-22-
LB475 LB475
2025 2025
1 (29) Remifentanil;
2 (30) Tapentadol; and
3 (31) Thiafentanil.
4 (c) Any material, compound, mixture, or preparation which contains
5 any quantity of the following substances having a potential for abuse
6 associated with a stimulant effect on the central nervous system:
7 (1) Amphetamine, its salts, optical isomers, and salts of its
8 optical isomers;
9 (2) Phenmetrazine and its salts;
10 (3) Methamphetamine, its salts, isomers, and salts of its isomers;
11 (4) Methylphenidate; and
12 (5) Lisdexamfetamine, its salts, isomers, and salts of its isomers.
13 (d) Any material, compound, mixture, or preparation which contains
14 any quantity of the following substances having a potential for abuse
15 associated with a depressant effect on the central nervous system,
16 including their salts, isomers, and salts of isomers whenever the
17 existence of such salts, isomers, and salts of isomers is possible within
18 the specific chemical designations:
19 (1) Amobarbital;
20 (2) Secobarbital;
21 (3) Pentobarbital;
22 (4) Phencyclidine; and
23 (5) Glutethimide.
24 (e) Hallucinogenic substances known as:
25 (1) Nabilone. Another name for nabilone: (+/-)-trans-3-(1,1-
26 dimethylheptyl)- 6,6a,7,8,10,10a-Hexahydro-1-hydroxy-6,6-dimethyl-9H-
27 dibenzo(b,d)pyran-9-one; and
28 (2) Dronabinol in an oral solution in a drug product approved by the
29 federal Food and Drug Administration.
30 (f) Unless specifically excepted or unless listed in another
31 schedule, any material, compound, mixture, or preparation which contains
-23-
LB475 LB475
2025 2025
1 any quantity of the following substances:
2 (1) Immediate precursor to amphetamine and methamphetamine:
3 Phenylacetone. Trade and other names shall include, but are not limited
4 to: Phenyl-2-propanone; P2P; benzyl methyl ketone; and methyl benzyl
5 ketone;
6 (2) Immediate precursors to phencyclidine, PCP:
7 (A) 1-phenylcyclohexylamine; or
8 (B) 1-piperidinocyclohexanecarbonitrile, PCC; or
9 (3) Immediate precursor to fentanyl; 4-anilino-N-phenethylpiperidine
10 (ANPP).
11 Schedule III
12 (a) Any material, compound, mixture, or preparation which contains
13 any quantity of the following substances having a potential for abuse
14 associated with a stimulant effect on the central nervous system,
15 including their salts, isomers, whether optical, position, or geometric,
16 and salts of such isomers whenever the existence of such salts, isomers,
17 and salts of isomers is possible within the specific chemical
18 designation:
19 (1) Benzphetamine;
20 (2) Chlorphentermine;
21 (3) Clortermine; and
22 (4) Phendimetrazine.
23 (b) Any material, compound, mixture, or preparation which contains
24 any quantity of the following substances having a potential for abuse
25 associated with a depressant effect on the central nervous system:
26 (1) Any substance which contains any quantity of a derivative of
27 barbituric acid or any salt of a derivative of barbituric acid, except
28 those substances which are specifically listed in other schedules of this
29 section;
30 (2) Aprobarbital;
31 (3) Butabarbital;
-24-
LB475 LB475
2025 2025
1 (4) Butalbital;
2 (5) Butethal;
3 (6) Butobarbital;
4 (7) Chlorhexadol;
5 (8) Embutramide;
6 (9) Lysergic acid;
7 (10) Lysergic acid amide;
8 (11) Methyprylon;
9 (12) Perampanel;
10 (13) Secbutabarbital;
11 (14) Sulfondiethylmethane;
12 (15) Sulfonethylmethane;
13 (16) Sulfonmethane;
14 (17) Nalorphine;
15 (18) Talbutal;
16 (19) Thiamylal;
17 (20) Thiopental;
18 (21) Vinbarbital;
19 (22) Any compound, mixture, or preparation containing amobarbital,
20 secobarbital, pentobarbital, or any salt thereof and one or more other
21 active medicinal ingredients which are not listed in any schedule;
22 (23) Any suppository dosage form containing amobarbital,
23 secobarbital, pentobarbital, or any salt of any of these drugs and
24 approved by the federal Food and Drug Administration for marketing only
25 as a suppository;
26 (24) Any drug product containing gamma-hydroxybutyric acid,
27 including its salts, isomers, and salts of isomers, for which an
28 application is approved under section 505 of the Federal Food, Drug, and
29 Cosmetic Act, 21 U.S.C. 355, as such section existed on January 1, 2014;
30 (25) Ketamine, its salts, isomers, and salts of isomers. Some other
31 names for ketamine: (+/-)-2-(2-chlorophenyl)-2-(methylamino)-
-25-
LB475 LB475
2025 2025
1 cyclohexanone; and
2 (26) Tiletamine and zolazepam or any salt thereof. Trade or other
3 names for a tiletamine-zolazepam combination product shall include, but
4 are not limited to: telazol. Trade or other names for tiletamine shall
5 include, but are not limited to: 2-(ethylamino)-2-(2-thienyl)-
6 cyclohexanone. Trade or other names for zolazepam shall include, but are
7 not limited to: 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-
8 trimethylpyrazolo-(3,4-e) (1,4)-diazepin-7(1H)-one, and flupyrazapon.
9 (c) Unless specifically excepted or unless listed in another
10 schedule:
11 (1) Any material, compound, mixture, or preparation containing
12 limited quantities of any of the following narcotic drugs, or any salts
13 calculated as the free anhydrous base or alkaloid, in limited quantities
14 as set forth below:
15 (A) Not more than one and eight-tenths grams of codeine per one
16 hundred milliliters or not more than ninety milligrams per dosage unit,
17 with an equal or greater quantity of an isoquinoline alkaloid of opium;
18 (B) Not more than one and eight-tenths grams of codeine per one
19 hundred milliliters or not more than ninety milligrams per dosage unit,
20 with one or more active, nonnarcotic ingredients in recognized
21 therapeutic amounts;
22 (C) Not more than one and eight-tenths grams of dihydrocodeine per
23 one hundred milliliters or not more than ninety milligrams per dosage
24 unit, with one or more active, nonnarcotic ingredients in recognized
25 therapeutic amounts;
26 (D) Not more than three hundred milligrams of ethylmorphine per one
27 hundred milliliters or not more than fifteen milligrams per dosage unit,
28 with one or more active, nonnarcotic ingredients in recognized
29 therapeutic amounts;
30 (E) Not more than five hundred milligrams of opium per one hundred
31 milliliters or per one hundred grams, or not more than twenty-five
-26-
LB475 LB475
2025 2025
1 milligrams per dosage unit, with one or more active, nonnarcotic
2 ingredients in recognized therapeutic amounts; and
3 (F) Not more than fifty milligrams of morphine per one hundred
4 milliliters or per one hundred grams with one or more active, nonnarcotic
5 ingredients in recognized therapeutic amounts; and
6 (2) Any material, compound, mixture, or preparation containing any
7 of the following narcotic drug or its salts, as set forth below:
8 (A) Buprenorphine.
9 (d) Unless contained on the list of exempt anabolic steroids of the
10 Drug Enforcement Administration of the United States Department of
11 Justice as the list existed on January 31, 2022, any anabolic steroid,
12 which shall include any material, compound, mixture, or preparation
13 containing any quantity of the following substances, including its salts,
14 isomers, and salts of isomers whenever the existence of such salts of
15 isomers is possible within the specific chemical designation:
16 (1) 3-beta,17-dihydroxy-5a-androstane;
17 (2) 3-alpha,17-beta-dihydroxy-5a-androstane;
18 (3) 5-alpha-androstan-3,17-dione;
19 (4) 1-androstenediol (3-beta,17-beta-dihydroxy-5-alpha-androst-1-
20 ene);
21 (5) 1-androstenediol (3-alpha,17-beta-dihydroxy-5-alpha-androst-1-
22 ene);
23 (6) 4-androstenediol (3-beta,17-beta-dihydroxy-androst-5-ene);
24 (7) 5-androstenediol (3-beta,17-beta-dihydroxy-androst-5-ene);
25 (8) 1-androstenedione ([5-alpha]-androst-1-en-3,17-dione);
26 (9) 4-androstenedione (androst-4-en-3,17-dione);
27 (10) 5-androstenedione (androst-5-en-3,17-dione);
28 (11) Bolasterone (7-alpha,17-alpha-dimethyl-17-beta-
29 hydroxyandrost-4-en-3-one);
30 (12) Boldenone (17-beta-hydroxyandrost-1,4-diene-3-one);
31 (13) Boldione (androsta-1,4-diene-3,17-3-one);
-27-
LB475 LB475
2025 2025
1 (14) Calusterone (7-beta,17-alpha-dimethyl-17-beta-hydroxyandrost-4-
2 en-3-one);
3 (15) Clostebol (4-chloro-17-beta-hydroxyandrost-4-en-3-one);
4 (16) Dehydrochloromethyltestosterone (4-chloro-17-beta-hydroxy-17-
5 alpha-methyl-androst-1,4-dien-3-one);
6 (17) Desoxymethyltestosterone (17-alpha-methyl-5-alpha-androst-2-
7 en-17-beta-ol) (a.k.a. 'madol');
8 (18) Delta-1-Dihydrotestosterone (a.k.a. '1-testosterone')(17-beta-
9 hydroxy-5-alpha-androst-1-en-3-one);
10 (19) 4-Dihydrotestosterone (17-beta-hydroxy-androstan-3-one);
11 (20) Drostanolone (17-beta-hydroxy-2-alpha-methyl-5-alpha-
12 androstan-3-one);
13 (21) Ethylestrenol (17-alpha-ethyl-17-beta-hydroxyestr-4-ene);
14 (22) Fluoxymesterone (9-fluoro-17-alpha-methyl-11-beta,17-beta-
15 dihydroxyandrost-4-en-3-one);
16 (23) Formebulone (formebolone); (2-formyl-17-alpha-methyl-11-
17 alpha,17-beta-dihydroxyandrost-1,4-dien-3-one);
18 (24) Furazabol (17-alpha-methyl-17-beta-hydroxyandrostano[2,3-c]-
19 furazan);
20 (25) 13-beta-ethyl-17-beta-hydroxygon-4-en-3-one;
21 (26) 4-hydroxytestosterone (4,17-beta-dihydroxy-androst-4-en-3-one);
22 (27) 4-hydroxy-19-nortestosterone (4,17-beta-dihydroxy-estr-4-en-3-
23 one);
24 (28) Mestanolone (17-alpha-methyl-17-beta-hydroxy-5-androstan-3-
25 one);
26 (29) Mesterolone (17-alpha-methyl-17-beta-hydroxy-5-androstan-3-
27 one);
28 (30) Methandienone (17-alpha-methyl-17-beta-hydroxyandrost-1,4-
29 dien-3-one);
30 (31) Methandriol (17-alpha-methyl-3-beta,17-beta-dihydroxyandrost-5-
31 ene);
-28-
LB475 LB475
2025 2025
1 (32) Methasterone (2-alpha,17-alpha-dimethyl-5-alpha-androstan-17-
2 beta-ol-3-one);
3 (33) Methenolone (1-methyl-17-beta-hydroxy-5-alpha-androst-1-en-3-
4 one);
5 (34) 17-alpha-methyl-3-beta,17-beta-dihydroxy-5a-androstane;
6 (35) 17-alpha-methyl-3-alpha,17-beta-dihydroxy-5a-androstane;
7 (36) 17-alpha-methyl-3-beta,17-beta-dihydroxyandrost-4-ene;
8 (37) 17-alpha-methyl-4-hydroxynandrolone (17-alpha-methyl-4-
9 hydroxy-17-beta-hydroxyestr-4-en-3-one);
10 (38) Methyldienolone (17-alpha-methyl-17-beta-hydroxyestra-4,9(10)-
11 dien-3-one);
12 (39) Methyltrienolone (17-alpha-methyl-17-beta-hydroxyestra-4,9,11-
13 trien-3-one);
14 (40) Methyltestosterone (17-alpha-methyl-17-beta-hydroxyandrost-4-
15 en-3-one);
16 (41) Mibolerone (7-alpha,17-alpha-dimethyl-17-beta-hydroxyestr-4-
17 en-3-one);
18 (42) 17-alpha-methyl-delta-1-dihydrotestosterone (17-beta-
19 hydroxy-17-alpha-methyl-5-alpha-androst-1-en-3-one) (a.k.a. '17-alpha-
20 methyl-1-testosterone');
21 (43) Nandrolone (17-beta-hydroxyestr-4-en-3-one);
22 (44) 19-nor-4-androstenediol (3-beta, 17-beta-dihydroxyestr-4-ene);
23 (45) 19-nor-4-androstenediol (3-alpha, 17-beta-dihydroxyestr-4-ene);
24 (46) 19-nor-5-androstenediol (3-beta, 17-beta-dihydroxyestr-5-ene);
25 (47) 19-nor-5-androstenediol (3-alpha, 17-beta-dihydroxyestr-5-ene);
26 (48) 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-
27 dione);
28 (49) 19-nor-4-androstenedione (estr-4-en-3,17-dione);
29 (50) 19-nor-5-androstenedione (estr-5-en-3,17-dione);
30 (51) Norbolethone (13-beta, 17-alpha-diethyl-17-beta-hydroxygon-4-
31 en-3-one);
-29-
LB475 LB475
2025 2025
1 (52) Norclostebol (4-chloro-17-beta-hydroxyestr-4-en-3-one);
2 (53) Norethandrolone (17-alpha-ethyl-17-beta-hydroxyestr-4-en-3-
3 one);
4 (54) Normethandrolone (17-alpha-methyl-17-beta-hydroxyestr-4-en-3-
5 one);
6 (55) Oxandrolone (17-alpha-methyl-17-beta-hydroxy-2-oxa-[5-alpha]-
7 androstan-3-one);
8 (56) Oxymesterone (17-alpha-methyl-4,17-beta-dihydroxyandrost-4-
9 en-3-one);
10 (57) Oxymetholone (17-alpha-methyl-2-hydroxymethylene-17-beta-
11 hydroxy-[5-alpha]-androstan-3-one);
12 (58) Prostanozol (17-beta-hydroxy-5-alpha-androstano[3,2-
13 c]pyrazole);
14 (59) Stanozolol (17-alpha-methyl-17-beta-hydroxy-[5-alpha]-
15 androst-2-eno[3,2-c]-pyrazole);
16 (60) Stenbolone (17-beta-hydroxy-2-methyl-[5-alpha]-androst-1-en-3-
17 one);
18 (61) Testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-
19 oic acid lactone);
20 (62) Testosterone (17-beta-hydroxyandrost-4-en-3-one);
21 (63) Tetrahydrogestrinone (13-beta, 17-alpha-diethyl-17-beta-
22 hydroxygon-4,9,11-trien-3-one);
23 (64) Trenbolone (17-beta-hydroxyestr-4,9,11-trien-3-one);
24 (65) [3,2-c]-furazan-5 alpha-androstane-17 beta-ol;
25 (66) [3,2-c]pyrazole-androst-4-en-17 beta-ol;
26 (67) 17 alpha-methyl-androst-ene-3,17 beta-diol;
27 (68) 17 alpha-methyl-androsta-1,4-diene-3,17 beta-diol;
28 (69) 17 alpha-methyl-androstan-3-hydroxyimine-17 beta-ol;
29 (70) 17 beta-hydroxy-androstano[2,3-d]isoxazole;
30 (71) 17 beta-hydroxy-androstano[3,2-c]isoxazole;
31 (72) 18a-homo-3-hydroxy-estra-2,5(10)-dien-17-one;
-30-
LB475 LB475
2025 2025
1 (73) 2 alpha, 3 alpha-epithio-17 alpha-methyl-5 alpha-androstan-17
2 beta-ol;
3 (74) 4-chloro-17 alpha-methyl-17 beta-hydroxy-androst-4-en-3-one;
4 (75) 4-chloro-17 alpha-methyl-17 beta-hydroxy-androst-4-en-3,11-
5 dione;
6 (76) 4-chloro-17 alpha-methyl-androst-4-ene-3 beta,17 beta-diol;
7 (77) 4-chloro-17 alpha-methyl-androsta-1,4-diene-3,17 beta-diol;
8 (78) 4-hydroxy-androst-4-ene-3,17-dione;
9 (79) 5 alpha-Androstan-3,6,17-trione;
10 (80) 6-bromo-androst-1,4-diene-3,17-dione;
11 (81) 6-bromo-androstan-3,17-dione;
12 (82) 6 alpha-methyl-androst-4-ene-3,17-dione;
13 (83) Delta 1-dihydrotestosterone;
14 (84) Estra-4,9,11-triene-3,17-dione; and
15 (85) Any salt, ester, or ether of a drug or substance described or
16 listed in this subdivision if the salt, ester, or ether promotes muscle
17 growth.
18 (e) Hallucinogenic substances known as:
19 (1) Dronabinol, synthetic, in sesame oil and encapsulated in a soft
20 gelatin capsule in a drug product approved by the federal Food and Drug
21 Administration. Some other names for dronabinol are (6aR-
22 trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo
23 (b,d)pyran-1-ol or (-)-delta-9-(trans)-tetrahydrocannabinol.
24 Schedule IV
25 (a) Any material, compound, mixture, or preparation which contains
26 any quantity of the following substances, including their salts, isomers,
27 and salts of isomers whenever the existence of such salts, isomers, and
28 salts of isomers is possible within the specific chemical designation:
29 (1) Barbital;
30 (2) Chloral betaine;
31 (3) Chloral hydrate;
-31-
LB475 LB475
2025 2025
1 (4) Chlordiazepoxide, but not including librax (chlordiazepoxide
2 hydrochloride and clindinium bromide) or menrium (chlordiazepoxide and
3 water soluble esterified estrogens);
4 (5) Clonazepam;
5 (6) Clorazepate;
6 (7) Daridorexant;
7 (8) Diazepam;
8 (9) Ethchlorvynol;
9 (10) Ethinamate;
10 (11) Flurazepam;
11 (12) Mebutamate;
12 (13) Meprobamate;
13 (14) Methohexital;
14 (15) Methylphenobarbital;
15 (16) Oxazepam;
16 (17) Paraldehyde;
17 (18) Petrichloral;
18 (19) Phenobarbital;
19 (20) Prazepam;
20 (21) Alprazolam;
21 (22) Bromazepam;
22 (23) Camazepam;
23 (24) Clobazam;
24 (25) Clotiazepam;
25 (26) Cloxazolam;
26 (27) Delorazepam;
27 (28) Estazolam;
28 (29) Ethyl loflazepate;
29 (30) Fludiazepam;
30 (31) Flunitrazepam;
31 (32) Halazepam;
-32-
LB475 LB475
2025 2025
1 (33) Haloxazolam;
2 (34) Ketazolam;
3 (35) Loprazolam;
4 (36) Lorazepam;
5 (37) Lormetazepam;
6 (38) Medazepam;
7 (39) Nimetazepam;
8 (40) Nitrazepam;
9 (41) Nordiazepam;
10 (42) Oxazolam;
11 (43) Pinazepam;
12 (44) Temazepam;
13 (45) Tetrazepam;
14 (46) Triazolam;
15 (47) Midazolam;
16 (48) Quazepam;
17 (49) Zolpidem;
18 (50) Dichloralphenazone;
19 (51) Zaleplon;
20 (52) Zopiclone;
21 (53) Fospropofol;
22 (54) Alfaxalone;
23 (55) Suvorexant;
24 (56) Carisoprodol;
25 (57) Brexanolone; 3 alpha-hydroxy-5 alpha-pregnan-20-one;
26 (58) Lemborexant;
27 (59) Solriamfetol; 2-amino-3-phenylpropyl carbamate;
28 (60) Remimazolam; and
29 (61) Serdexmethylphenidate; and .
30 (62) Tianeptine.
31 (b) Any material, compound, mixture, or preparation which contains
-33-
LB475 LB475
2025 2025
1 any quantity of the following substance, including its salts, isomers,
2 whether optical, position, or geometric, and salts of such isomers,
3 whenever the existence of such salts, isomers, and salts of isomers is
4 possible: Fenfluramine.
5 (c) Unless specifically excepted or unless listed in another
6 schedule, any material, compound, mixture, or preparation which contains
7 any quantity of the following substances having a stimulant effect on the
8 central nervous system, including their salts, isomers, whether optical,
9 position, or geometric, and salts of such isomers whenever the existence
10 of such salts, isomers, and salts of isomers is possible within the
11 specific chemical designation:
12 (1) Diethylpropion;
13 (2) Phentermine;
14 (3) Pemoline, including organometallic complexes and chelates
15 thereof;
16 (4) Mazindol;
17 (5) Pipradrol;
18 (6) SPA, ((-)-1-dimethylamino-1,2-diphenylethane);
19 (7) Cathine. Another name for cathine is ((+)-norpseudoephedrine);
20 (8) Fencamfamin;
21 (9) Fenproporex;
22 (10) Mefenorex;
23 (11) Modafinil; and
24 (12) Sibutramine.
25 (d) Unless specifically excepted or unless listed in another
26 schedule, any material, compound, mixture, or preparation which contains
27 any quantity of the following narcotic drugs, or their salts or isomers
28 calculated as the free anhydrous base or alkaloid, in limited quantities
29 as set forth below:
30 (1) Propoxyphene in manufactured dosage forms;
31 (2) Not more than one milligram of difenoxin and not less than
-34-
LB475 LB475
2025 2025
1 twenty-five micrograms of atropine sulfate per dosage unit; and
2 (3) 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its
3 salts, optical and geometric isomers, and salts of these isomers to
4 include: Tramadol.
5 (e) Unless specifically excepted or unless listed in another
6 schedule, any material, compound, mixture, or preparation which contains
7 any quantity of the following substances substance, including their its
8 salts:
9 (1) Pentazocine; and
10 (2) Butorphanol (including its optical isomers).
11 (f) Any material, compound, mixture, or preparation which contains
12 any quantity of the following substance substances, including its salts,
13 isomers, and salts of such isomers, whenever the existence of such salts,
14 isomers, and salts of isomers is possible: Lorcaserin.
15 (g)(1) Unless specifically excepted or unless listed in another
16 schedule, any material, compound, mixture, or preparation which contains
17 any quantity of the following substance, including its salts, optical
18 isomers, and salts of such optical isomers: Ephedrine.
19 (2) The following drug products containing ephedrine, its salts,
20 optical isomers, and salts of such optical isomers, are excepted from
21 subdivision (g)(1) of Schedule IV if they (A) are stored behind a
22 counter, in an area not accessible to customers, or in a locked case so
23 that a customer needs assistance from an employee to access the drug
24 product; (B) are sold by a person, eighteen years of age or older, in the
25 course of his or her employment to a customer eighteen years of age or
26 older with the following restrictions: No customer shall be allowed to
27 purchase, receive, or otherwise acquire more than three and six-tenths
28 grams of ephedrine base during a twenty-four-hour period; no customer
29 shall purchase, receive, or otherwise acquire more than nine grams of
30 ephedrine base during a thirty-day period; and the customer shall display
31 a valid driver's or operator's license, a Nebraska state identification
-35-
LB475 LB475
2025 2025
1 card, a military identification card, an alien registration card, or a
2 passport as proof of identification; (C) are labeled and marketed in a
3 manner consistent with the pertinent OTC Tentative Final or Final
4 Monograph; (D) are manufactured and distributed for legitimate medicinal
5 use in a manner that reduces or eliminates the likelihood of abuse; and
6 (E) are not marketed, advertised, or represented in any manner for the
7 indication of stimulation, mental alertness, euphoria, ecstasy, a buzz or
8 high, heightened sexual performance, or increased muscle mass:
9 (i) Primatene Tablets; and
10 (ii) Bronkaid Dual Action Caplets.
11 Schedule V
12 (a) Any compound, mixture, or preparation containing any of the
13 following limited quantities of narcotic drugs or salts calculated as the
14 free anhydrous base or alkaloid, which shall include one or more
15 nonnarcotic active medicinal ingredients in sufficient proportion to
16 confer upon the compound, mixture, or preparation valuable medicinal
17 qualities other than those possessed by the narcotic drug alone:
18 (1) Not more than two hundred milligrams of codeine per one hundred
19 milliliters or per one hundred grams;
20 (2) Not more than one hundred milligrams of dihydrocodeine per one
21 hundred milliliters or per one hundred grams;
22 (3) Not more than one hundred milligrams of ethylmorphine per one
23 hundred milliliters or per one hundred grams;
24 (4) Not more than two and five-tenths milligrams of diphenoxylate
25 and not less than twenty-five micrograms of atropine sulfate per dosage
26 unit;
27 (5) Not more than one hundred milligrams of opium per one hundred
28 milliliters or per one hundred grams; and
29 (6) Not more than five-tenths milligram of difenoxin and not less
30 than twenty-five micrograms of atropine sulfate per dosage unit.
31 (b) Unless specifically exempted or excluded or unless listed in
-36-
LB475 LB475
2025 2025
1 another schedule, any material, compound, mixture, or preparation which
2 contains any quantity of the following substances having a stimulant
3 effect on the central nervous system, including its salts, isomers, and
4 salts of isomers: Pyrovalerone.
5 (c) Unless specifically exempted or excluded or unless listed in
6 another schedule, any material, compound, mixture, or preparation which
7 contains any quantity of the following substances having a depressant
8 effect on the central nervous system, including its salts, isomers, and
9 salts of isomers:
10 (1) Ezogabine (N-(2-amino-4-(4-fluorobenzylamino)-phenyl)-carbamic
11 acid ethyl ester);
12 (2) Ganaxolone;
13 (3) Lacosamide ((R)-2-acetoamido-N-benzyl-3-methoxy-propionamide);
14 (4) Pregabalin ((S)-3-(aminomethyl)-5-methylhexanoic acid);
15 (5) Brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]
16 butanamide) (also referred to as BRV; UCB-34714; Briviact), including its
17 salts;
18 (6) Cenobamate; and
19 (7) Lasmiditan.
20 Sec. 2. Original section 28-405, Revised Statutes Cumulative
21 Supplement, 2024, is repealed.
-37-
[DELETED: yRAs 2 R S C S 2 tc t a a c s a t r toB5L52]
[DELETED: S 1 S 2 R S C S22 T f a t s o c src o t l o e p o t D EA o t U S D o J a t leS(0e s a s o i e a e u1s e w t e o s i e2e3(4(5(6k7(8(9(0(1(2(3(4(5(6(7(8(9(0(1(5L52]
[DELETED: (((((((((0(1(2(3(4(5(6(7(8(9(0(1(2(3(4(5(6( A N7p p 18p9(0(1p5L52]
[DELETED: i( 1 ( i oi( P 1 io( A Npi( A N0p i o i s a s1o2( B N3i4( B N5p i o i s a s6o7( B ( n N8p i o a9g0( 3 N1p i o a g i2s3( N4(5( T N6p7( P N8p i o i s a s o9i0( U 31m5L52]
[DELETED: (((( A 3 4 cb((((0(1(2(3(4(5(6y7(8(9(0(1(2(3(4(5(6(7(8(9(0(1(5L52]
[DELETED: ((((((( B ( n 1 ep( F s t i e e0s a s o i e a e U s1e l i a s o s n i t2s t i a s t i s r t3f4(5m6(7a8(9a0( R o t a r w a a m1w2(3( A o t f o d t s i4a s o i u s e w t5e6t7(8(9(0(1(5L52]
[DELETED: (((((((((0(1(2(3(4(5(6(7(8(9(0a q o t f h s t s1i2e3t4o5( B T a o n s i b a n6l t 3 37d N 58d9( 4 T a o n s0i b a n l t 41m5L52]
[DELETED: (a n l t 4 ap( 4 T a o n si b a n l t 4m( P T a o n si b a n l t 1a0( I T a o n s i b a n1l t 72m ( a ( i a T3i4(5(6(7(8( P P s m a p o t p p9c0o1e2o3(4(5(6e7e o c s o s s d a8t i w s c s a p9a0a t o i e d i a d p1a b t f F a D A D 6 c o5L52]
[DELETED: too t s i n i s c ot s s b i r o t ndiF((0(1i223(4( P T a o n s i b a n5l t 36d7(8i b a n l t N (9p N0c1( P a o p T a o n2s i b a n l t 13p4(5M a 3 i6a7(8(9(0( S d o S A S d o1S A i a p o t p p c5L52]
[DELETED: b a S d w g o n t st a e f a p o s p a e cm d m o p o s p iswp(q( t ( o t s i t s i0s1u s e e i t s S2n o t s p c i n3i4o c o t s s b i u t5s6p7m o s t o a t t s c8p9( T M t n0c1s2r e o c s a s s3d a t i w s c s a4p a s a t f D 1 c o t5t a t o i D 6 c o t6t7t8i9F0( N A c c a 31n5L52]
[DELETED: i r b a a h a h bc c 2 gc 1 1p 1 oto( N A c c a 1 Hyo0c c 2 g1c 1 12p 1 o3t4o5( N A c c a 36n7p r b a a h a h b8c c 2 g9c 1 10p 1 o1t2o3( N A c c 4n5i r b a a h a h b6c c 2 g7c 1 18p 1 o9t0o1( P A c c a 35L52]
[DELETED: p s w s a t n a ot i r b a a h a h bc c 2 gc 1 1p 1 oto( C A c c a 2h0t p r b a a h a h b1c c 2 g2c 1 13p 1 o4t5t6( B A c c a 37s8a h a h b c9c0p 1 11m o t g w o n2f s i o o a o t l r s t a3e4(5s6a h c a h b7c c 1829m o t g w o n0f s i o o a o t l r s t a1e5L52]
[DELETED: ( T A c c a 3t s w s a tn a o t i r b a a h ca h b c c 1m 2 1p 1 oto( I c A c c a 10c s w s a t n a o t1i r b a a h c a h2b c c 13p 2 14p 1 o5t6a a m b p a 17p8s9t a 1 p a b o0p1( I c A c c a 12c s w s a t n a o t3i r b a a h c a h4b c c 15p 2 16p 1 o7t8a a m b p a 19p0s1t a 1 p a b o5L52]
[DELETED: p( A n o s c cm o p n s l e i tsF a D A c o c a cr( Z 1y i i i e e sa0i e e a s i p w t s1c2(3q o a s p a l i s (4t5a s o s n i t s t i6s d f p b s o t7p r w a f m r f f r o 8f t r b s w t a g b9s0o1s f a c o t f t o2t r s w o n t c i f3m4( S o t p r b a h h a5t6p7a8a9(0a1(5L52]
[DELETED: a(a(o(2(a0( 2 w i a1k2( 2 w i3a4( 2 w i5a6( 2 w i a k7a8(9k0( 1 w i a1k2(3k4(5k6( 27m8N9( 20m1N5L52]
[DELETED: ( Nw i a k a M o 3m( 2m w i a k a 2 o2( 2w( 2 [0y1( 22y3( N t4b w i a k a 25N6( 17w i a k a b o b8d9(0i1(2(3(4a5( 6 w i a6k7( 2 w i a k a 2 58d9(0( 2 w i a1k5L52]
[DELETED: ((4(( 3 w i a k aM( 3 w i a ka(0( n 4 w1i2(3q4i a s o s n i t s t i5s d f 2 w i a6k7w8i9a t a p w a a g o w o n f0s o t i r t a e w a a a1h2( 5 w i a k a 53D4(5D6(7H8( 4 w i a k a 49H0(155L52]
[DELETED: (D( 5 w i a k a 5M(D(( A s c a q o t fm0(1(2(3(4(5(6( B o b o7b8(9a0b t i s d b a m f 21a2n o t r s w o n t c i3f4( S i t r s t a e w a5a a h h o h s6w o n f s i t r s b o o m7o8( S a t 3 w a a a9s0( S a t 2 n a w a o1d5L52]
[DELETED: s( U s e o u l i asati w t e o s s i a s oi( A 7y a i i s i a s o0i1(2(3(4h 4 4 A S5O6( U s e o u l i a7s8a9c n s i i s i a s o0i1(2(3( A a 2 o 44d5( C 2 a6a7(8i S o n 2 a9( 2 a0N m m1e5L52]
[DELETED: ( ( a (p( N Na(( 4 ( n 4 4m( N - pi i i s i a s o0i1( A c s a t t e i f2h3S4( A o t f s e t n d5l i o s w p d o i b6e7c s o b c o e a c8s9( O a o a a s c d o0p o o o o e a b1t b d n n2n3(4(5(6(7(8(9(0(1(5L52]
[DELETED: (((((((((0(1c2t3s4(5(6o c l a a s c d o p7t8s9a s o o i e t t s s n0i d c l o e w d n c1c2(3e l s o p f w c t p4a5(6o7a8s9c0(1(5L52]
[DELETED: ((((((((( M 40b1( M 22d3(4(5(6(7( P e8c9( P 10c1(2(3(4(5(6(7(8(9( L w i a k a l0a1(5L52]
[DELETED: ((((a q o t f s h a p f aa( A i s o i a s o io(0(1(2(3(4a q o t f s h a p f a5a w a d e o t c n s6i t s i a s o i w t7e8t9(0(1(2(3(4(5( N A n f n (6d 67d8(9f0( U s e o u l i a1s5L52]
[DELETED: a( I p t a a mPt P P b m k a m bk((((0(1S2(3a q o t f s h a p f a4a w a s e o t c n s5i6a7a s o i i p w t s c8d9(0(1(2(3(4a q o t f s h a p f a5a6( A s w c a q o a d o7b8t9s0(1(5L52]
[DELETED: (((((((((0(1(2(3(4(5(6(7(8(9( A c m o p c a0s1a2( A s d f c a3s p o a s o a o t d a4a5a6( A d p c g a7i i s i a s o i f w a8a9C0(1n f k (5L52]
[DELETED: c( T a z o a s t T o onai b a n l t 2cn l t 4t( U s e o u l i a0s1( A m c m o p c2l3c4a5( N m t o a e g o c p o6h7w8( N m t o a e g o c p o9h0w o o m a n i i r1t2(3o h m o n m t n m p d4u w o o m a n i i r5t6(7h8w o o m a n i i r9t0(1m o p o h g o n m t t5L52]
[DELETED: m p d u w o o m a ni( N m t f m o m p o hmi(o((0D E A o t U S D o1J2w s i a m c m o p3c4i a s o i w t e o s s o5i6(7(8(9( 1 (0e1( 1 (2e3(4(5(6(7(8( B (9h0(1(5L52]
[DELETED: (e(( D (a( D (e( D ( 'h0(1( D (2a3(4( F (5d6( F ( (7a8( F (9f0(1(2( 4 (3o4( M (5o6( M (7o8( M (9d0(1e5L52]
[DELETED: ( M (b( M (o(((( 1 (h0( M (1d2( M (3t4( M (5e6( M (7e8( 1 (9h ( '0m1(2(3(4(5(6( 1 (7d8(9(0( N ( 11e5L52]
[DELETED: (( N (o( N (o( O (a( O (e0( O (1h2( P (3c4( S (5a6( S (7o8( T (9o0(1( T ( 12h3(4(5(6(7(8(9(0(1(5L52]
[DELETED: ( 2 a 3 a a ab(( 4 a bd((((0(1(2(3(4(5(6l7g8(9(0g1A S o n f d a (2t3(4S5(6a7a8s9(0(1(5L52]
[DELETED: ( C b n i l (h a c b o m ( aw((((((0(1(2(3(4(5(6(7(8(9(0(1(2(3(4(5(6(7(8(9(0(1(5L52]
[DELETED: (((((((((0(1(2(3(4(5(6(7(8(9(0(1(2(3(4(5(6(7(8(9(0(1(5L52]
[DELETED: a q o t f s i i s iw o p o g a s o s iwp( U s e o u l i asacp0o s s i a s o i i p w t1s2(3(4( P i o c a c5t6(7(8(9(0(1(2(3(4(5( U s e o u l i a6s7a8c9a0(1( N m t o m o d a n l t5L52]
[DELETED: t( 2 is o a g i a s o t i ti( U s e o u l i asas(0(1(2a3i4i5( U s e o u l i a6s7a q o t f s i i s o8i9( T f d p c e i s0o i a s o s o i a e f1s ( o S I i t ( a s b 2c3t a c n a f a e t a t d4p5c6o7p r o o a m t t a s8g o e b d a t p n c9s p r o o a m t n g o0e1a5L52]
[DELETED: cpm c w t p O T F o FMu(ih(0(1S2( A c m o p c a o t3f4f a b o a w s i o o m5n a m i i s p t6c u t c m o p v m7q8(9m0(1h2( N m t o h m o e p o3h4( N m t t a f m o d5a6u7(8m9( N m t f m o d a n l0t1( U s e o e o u l i5L52]
[DELETED: ac a q o t f s h a ses( U s e o e o u l iac a q o t f s h a des0( E (1a2(3(4(5( B (6b7s8(9(0S 2  O s 2 R S C1S5L52]


================================================================================

Raw Text:
LB475 LB475
2025 2025
LEGISLATURE OF NEBRASKA
ONE HUNDRED NINTH LEGISLATURE
FIRST SESSION
LEGISLATIVE BILL 475
Introduced by Riepe, 12.
Read first time January 21, 2025
Committee: Judiciary
1 A BILL FOR AN ACT relating to Uniform controlled Substances Act; to amend
2 section 28-405, Revised Statutes Cumulative Supplement, 2024; to
3 classify tianeptine as a controlled substance; and to repeal the
4 original section.
5 Be it enacted by the people of the State of Nebraska,
-1-

LB475 LB475
2025 2025
1 Section 1. Section 28-405, Revised Statutes Cumulative Supplement,
2 2024, is amended to read:
3 28-405 The following are the schedules of controlled substances
4 referred to in the Uniform Controlled Substances Act, unless specifically
5 contained on the list of exempted products of the Drug Enforcement
6 Administration of the United States Department of Justice as the list
7 existed on January 31, 2022:
8 Schedule I
9 (a) Any of the following opiates, including their isomers, esters,
10 ethers, salts, and salts of isomers, esters, and ethers, unless
11 specifically excepted, whenever the existence of such isomers, esters,
12 ethers, and salts is possible within the specific chemical designation:
13 (1) Acetylmethadol;
14 (2) Allylprodine;
15 (3) Alphacetylmethadol, except levo-alphacetylmethadol which is also
16 known as levo-alpha-acetylmethadol, levomethadyl acetate, and LAAM;
17 (4) Alphameprodine;
18 (5) Alphamethadol;
19 (6) Benzethidine;
20 (7) Betacetylmethadol;
21 (8) Betameprodine;
22 (9) Betamethadol;
23 (10) Betaprodine;
24 (11) Clonitazene;
25 (12) Dextromoramide;
26 (13) Difenoxin;
27 (14) Diampromide;
28 (15) Diethylthiambutene;
29 (16) Dimenoxadol;
30 (17) Dimepheptanol;
31 (18) Dimethylthiambutene;
-2-

LB475 LB475
2025 2025
1 (19) Dioxaphetyl butyrate;
2 (20) Dipipanone;
3 (21) Ethylmethylthiambutene;
4 (22) Etonitazene;
5 (23) Etoxeridine;
6 (24) Furethidine;
7 (25) Hydroxypethidine;
8 (26) Ketobemidone;
9 (27) Levomoramide;
10 (28) Levophenacylmorphan;
11 (29) Morpheridine;
12 (30) Noracymethadol;
13 (31) Norlevorphanol;
14 (32) Normethadone;
15 (33) Norpipanone;
16 (34) Phenadoxone;
17 (35) Phenampromide;
18 (36) Phenomorphan;
19 (37) Phenoperidine;
20 (38) Piritramide;
21 (39) Proheptazine;
22 (40) Properidine;
23 (41) Propiram;
24 (42) Racemoramide;
25 (43) Trimeperidine;
26 (44) Alpha-methylfentanyl, N-(1-(alpha-methyl-beta-phenyl)ethyl-4-
27 piperidyl) propionanilide, 1-(1-methyl-2-phenylethyl)-4-(N-propanilido)
28 piperidine;
29 (45) Tilidine;
30 (46) 3-Methylfentanyl, N-(3-methyl-1-(2-phenylethyl)-4-piperidyl)-N-
31 phenylpropanamide, its optical and geometric isomers, salts, and salts of
-3-

LB475 LB475
2025 2025
1 isomers;
2 (47) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP), its optical
3 isomers, salts, and salts of isomers;
4 (48) PEPAP, 1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine, its
5 optical isomers, salts, and salts of isomers;
6 (49) Acetyl-alpha-methylfentanyl, N-(1-(1-methyl-2-phenethyl)-4-
7 piperidinyl)-N-phenylacetamide, its optical isomers, salts, and salts of
8 isomers;
9 (50) Alpha-methylthiofentanyl, N-(1-methyl-2-(2-thienyl)ethyl-4-
10 piperidinyl)-N-phenylpropanamide, its optical isomers, salts, and salts
11 of isomers;
12 (51) Benzylfentanyl, N-(1-benzyl-4-piperidyl)-N-phenylpropanamide,
13 its optical isomers, salts, and salts of isomers;
14 (52) Beta-hydroxyfentanyl, N-(1-(2-hydroxy-2-phenethyl)-4-
15 piperidinyl)-N-phenylpropanamide, its optical isomers, salts, and salts
16 of isomers;
17 (53) Beta-hydroxy-3-methylfentanyl, (other name: N-(1-(2-hydroxy-2-
18 phenethyl)-3-methyl-4-piperidinyl)-N-phenylpropanamide), its optical and
19 geometric isomers, salts, and salts of isomers;
20 (54) 3-methylthiofentanyl, N-(3-methyl-1-(2-thienyl)ethyl-4-
21 piperidinyl)-N-phenylpropanamide, its optical and geometric isomers,
22 salts, and salts of isomers;
23 (55) N-(1-(2-thienyl)methyl-4-piperidyl)-N-phenylpropanamide
24 (thenylfentanyl), its optical isomers, salts, and salts of isomers;
25 (56) Thiofentanyl, N-phenyl-N-(1-(2-thienyl)ethyl-4-piperidinyl)-
26 propanamide, its optical isomers, salts, and salts of isomers;
27 (57) Para-fluorofentanyl, N-(4-fluorophenyl)-N-(1-(2-phenethyl)-4-
28 piperidinyl)propanamide, its optical isomers, salts, and salts of
29 isomers;
30 (58) U-47700, 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-
31 methylbenzamide;
-4-

LB475 LB475
2025 2025
1 (59) 4-Fluoroisobutyryl Fentanyl;
2 (60) Acetyl Fentanyl;
3 (61) Acyrloylfentanyl;
4 (62) AH-7921; 3, 4-dichloro-N-[(1-dimethylamino) cyclohexylmethyl]
5 benzamide;
6 (63) Butyryl fentanyl;
7 (64) Cyclopentyl fentanyl;
8 (65) Cyclopropyl fentanyl;
9 (66) Furanyl fentanyl;
10 (67) Isobutyryl fentanyl;
11 (68) Isotonitazene;
12 (69) Methoxyacetyl fentanyl;
13 (70) MT-45; 1-cyclohexyl-4-(1,2-diphenylethyl) piperazine;
14 (71) Tetrahydrofuranyl fentanyl;
15 (72) 2-fluorofentanyl; N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-
16 yl) propionamide;
17 (73) Ocfentanil;
18 (74) Ortho-Fluorofentanyl;
19 (75) Para-chloroisobutyryl fentanyl;
20 (76) Para-Fluorobutyryl Fentanyl;
21 (77) Valeryl fentanyl;
22 (78) Phenyl Fentanyl;
23 (79) Para-Methylfentanyl;
24 (80) Thiofuranyl Fentanyl;
25 (81) Beta-methyl Fentanyl;
26 (82) Beta'-Phenyl Fentanyl;
27 (83) Crotonyl Fentanyl;
28 (84) 2'-Fluoro Ortho-Fluorofentanyl;
29 (85) 4'-Methyl Acetyl Fentanyl;
30 (86) Ortho-Fluorobutyryl Fentanyl;
31 (87) Ortho-Methyl Acetylfentanyl;
-5-

LB475 LB475
2025 2025
1 (88) Ortho-Methyl Methoxyacetyl Fentanyl;
2 (89) Ortho-Fluoroacryl Fentanyl;
3 (90) Fentanyl Carbamate;
4 (91) Ortho-Fluoroisobutyryl Fentanyl;
5 (92) Para-Fluoro Furanyl Fentanyl;
6 (93) Para-Methoxybutyryl Fentanyl;
7 (94) Brorphine (other name: 1-(1-(1-(4-bromophenyl) ethyl)
8 piperidin-4-yl-1,3-dihydro-2H-benzo[D]imidazole-2-one); and
9 (95) Fentanyl-related substances, their isomers, esters, ethers,
10 salts and salts of isomers, esters, and ethers. Unless specifically
11 excepted, listed in another schedule, or specifically named in this
12 schedule, this includes any substance that is structurally related to
13 fentanyl by one or more of the following modifications:
14 (A) Replacement of the phenyl portion of the phenethyl group by any
15 monocycle, whether or not further substituted in or on the monocycle;
16 (B) Substitution in or on the phenethyl group with alkyl, alkenyl,
17 alkoxyl, hydroxyl, halo, haloalkyl, amino, or nitro groups;
18 (C) Substitution in or on the piperidine ring with alkyl, alkenyl,
19 alkoxyl, ester, ether, hydroxyl, halo, haloalkyl, amino, or nitro groups;
20 (D) Replacement of the aniline ring with any aromatic monocycle
21 whether or not further substituted in or on the aromatic monocycle; or
22 (E) Replacement of the N-propionyl group by another acyl group.
23 (b) Any of the following opium derivatives, their salts, isomers,
24 and salts of isomers, unless specifically excepted, whenever the
25 existence of such salts, isomers, and salts of isomers is possible within
26 the specific chemical designation:
27 (1) Acetorphine;
28 (2) Acetyldihydrocodeine;
29 (3) Benzylmorphine;
30 (4) Codeine methylbromide;
31 (5) Codeine-N-Oxide;
-6-

LB475 LB475
2025 2025
1 (6) Cyprenorphine;
2 (7) Desomorphine;
3 (8) Dihydromorphine;
4 (9) Drotebanol;
5 (10) Etorphine, except hydrochloride salt;
6 (11) Heroin;
7 (12) Hydromorphinol;
8 (13) Methyldesorphine;
9 (14) Methyldihydromorphine;
10 (15) Morphine methylbromide;
11 (16) Morphine methylsulfonate;
12 (17) Morphine-N-Oxide;
13 (18) Myrophine;
14 (19) Nicocodeine;
15 (20) Nicomorphine;
16 (21) Normorphine;
17 (22) Pholcodine; and
18 (23) Thebacon.
19 (c) Any material, compound, mixture, or preparation which contains
20 any quantity of the following hallucinogenic substances, their salts,
21 isomers, and salts of isomers, unless specifically excepted, whenever the
22 existence of such salts, isomers, and salts of isomers is possible within
23 the specific chemical designation, and, for purposes of this subdivision
24 only, isomer shall include the optical, position, and geometric isomers:
25 (1) Bufotenine. Trade and other names shall include, but are not
26 limited to: 3-(beta-Dimethylaminoethyl)-5-hydroxyindole; 3-(2-
27 dimethylaminoethyl)-5-indolol; N,N-dimethylserotonin; 5-hydroxy-N,N-
28 dimethyltryptamine; and mappine;
29 (2) 4-bromo-2,5-dimethoxyamphetamine. Trade and other names shall
30 include, but are not limited to: 4-bromo-2,5-dimethoxy-alpha-
31 methylphenethylamine; and 4-bromo-2,5-DMA;
-7-

LB475 LB475
2025 2025
1 (3) 4-methoxyamphetamine. Trade and other names shall include, but
2 are not limited to: 4-methoxy-alpha-methylphenethylamine; and
3 paramethoxyamphetamine, PMA;
4 (4) 4-methyl-2,5-dimethoxyamphetamine. Trade and other names shall
5 include, but are not limited to: 4-methyl-2,5-dimethoxy-alpha-
6 methylphenethylamine; DOM; and STP;
7 (5) Para-methoxymethamphetamine. Trade and other names shall
8 include, but are not limited to: 1-(4-Methoxyphenyl)-N-methylpropan-2-
9 amine, PMMA, and 4-MMA;
10 (6) Ibogaine. Trade and other names shall include, but are not
11 limited to: 7-Ethyl-6,6beta,7,8,9,10,12,13-octahydro-2-methoxy-6,9-
12 methano-5H-pyrido (1',2':1,2) azepino (5,4-b) indole; and Tabernanthe
13 iboga;
14 (7) Lysergic acid diethylamide;
15 (8) Marijuana;
16 (9) Mescaline;
17 (10) Methoxetamine (MXE);
18 (11) Peyote. Peyote shall mean all parts of the plant presently
19 classified botanically as Lophophora williamsii Lemaire, whether growing
20 or not, the seeds thereof, any extract from any part of such plant, and
21 every compound, manufacture, salts, derivative, mixture, or preparation
22 of such plant or its seeds or extracts;
23 (12) Psilocybin;
24 (13) Psilocyn;
25 (14) Tetrahydrocannabinols, including, but not limited to, synthetic
26 equivalents of the substances contained in the plant or in the resinous
27 extractives of cannabis, sp. or synthetic substances, derivatives, and
28 their isomers with similar chemical structure and pharmacological
29 activity such as the following: Delta 1 cis or trans tetrahydrocannabinol
30 and their optical isomers, excluding dronabinol in a drug product
31 approved by the federal Food and Drug Administration; Delta 6 cis or
-8-

LB475 LB475
2025 2025
1 trans tetrahydrocannabinol and their optical isomers; and Delta 3,4 cis
2 or trans tetrahydrocannabinol and its optical isomers. Since nomenclature
3 of these substances is not internationally standardized, compounds of
4 these structures shall be included regardless of the numerical
5 designation of atomic positions covered. Tetrahydrocannabinols does not
6 include cannabidiol contained in a drug product approved by the federal
7 Food and Drug Administration;
8 (15) N-ethyl-3-piperidyl benzilate;
9 (16) N-methyl-3-piperidyl benzilate;
10 (17) Thiophene analog of phencyclidine. Trade and other names shall
11 include, but are not limited to: 1-(1-(2-thienyl)-cyclohexyl)-piperidine;
12 2-thienyl analog of phencyclidine; TPCP; and TCP;
13 (18) Hashish or concentrated cannabis;
14 (19) Parahexyl. Trade and other names shall include, but are not
15 limited to: 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
16 dibenzo(b,d)pyran; and Synhexyl;
17 (20) Ethylamine analog of phencyclidine. Trade and other names shall
18 include, but are not limited to: N-ethyl-1-phenylcyclohexylamine; (1-
19 phenylcyclohexyl)ethylamine; N-(1-phenylcyclohexyl)ethylamine;
20 cyclohexamine; and PCE;
21 (21) Pyrrolidine analog of phencyclidine. Trade and other names
22 shall include, but are not limited to: 1-(1-phenylcyclohexyl)-
23 pyrrolidine; PCPy; and PHP;
24 (22) Alpha-ethyltryptamine. Some trade or other names: etryptamine;
25 Monase; alpha-ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl) indole;
26 alpha-ET; and AET;
27 (23) 2,5-dimethoxy-4-ethylamphet-amine; and DOET;
28 (24) 1-(1-(2-thienyl)cyclohexyl)pyrrolidine; and TCPy;
29 (25) Alpha-methyltryptamine, which is also known as AMT;
30 (26) Salvia divinorum or Salvinorin A. Salvia divinorum or
31 Salvinorin A includes all parts of the plant presently classified
-9-

LB475 LB475
2025 2025
1 botanically as Salvia divinorum, whether growing or not, the seeds
2 thereof, any extract from any part of such plant, and every compound,
3 manufacture, derivative, mixture, or preparation of such plant, its
4 seeds, or its extracts, including salts, isomers, and salts of isomers
5 whenever the existence of such salts, isomers, and salts of isomers is
6 possible within the specific chemical designation;
7 (27) Any material, compound, mixture, or preparation containing any
8 quantity of synthetically produced cannabinoids as listed in subdivisions
9 (A) through (L) of this subdivision, including their salts, isomers,
10 salts of isomers, and nitrogen, oxygen, or sulfur-heterocyclic analogs,
11 unless specifically excepted elsewhere in this section. Since
12 nomenclature of these synthetically produced cannabinoids is not
13 internationally standardized and may continually evolve, these structures
14 or compounds of these structures shall be included under this
15 subdivision, regardless of their specific numerical designation of atomic
16 positions covered, so long as it can be determined through a recognized
17 method of scientific testing or analysis that the substance contains
18 properties that fit within one or more of the following categories:
19 (A) Tetrahydrocannabinols: Meaning tetrahydrocannabinols naturally
20 contained in a plant of the genus cannabis (cannabis plant), as well as
21 synthetic equivalents of the substances contained in the plant, or in the
22 resinous extractives of cannabis, sp. and/or synthetic substances,
23 derivatives, and their isomers with similar chemical structure and
24 pharmacological activity such as the following: Delta 1 cis or trans
25 tetrahydrocannabinol, and their optical isomers; Delta 6 cis or trans
26 tetrahydrocannabinol, and their optical isomers; Delta 3,4 cis or trans
27 tetrahydrocannabinol, and its optical isomers. This subdivision does not
28 include cannabidiol contained in a drug product approved by the federal
29 Food and Drug Administration;
30 (B) Naphthoylindoles: Any compound containing a 3-(1-
31 naphthoyl)indole structure with substitution at the nitrogen atom of the
-10-

LB475 LB475
2025 2025
1 indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
2 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
3 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
4 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
5 tetrahydropyranylmethyl group, whether or not further substituted in or
6 on any of the listed ring systems to any extent;
7 (C) Naphthylmethylindoles: Any compound containing a 1 H-indol-3-
8 yl-(1-naphthyl)methane structure with substitution at the nitrogen atom
9 of the indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
10 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
11 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
12 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
13 tetrahydropyranylmethyl group, whether or not further substituted in or
14 on any of the listed ring systems to any extent;
15 (D) Naphthoylpyrroles: Any compound containing a 3-(1-
16 naphthoyl)pyrrole structure with substitution at the nitrogen atom of the
17 pyrrole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
18 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
19 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
20 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
21 tetrahydropyranylmethyl group, whether or not further substituted in or
22 on any of the listed ring systems to any extent;
23 (E) Naphthylideneindenes: Any compound containing a
24 naphthylideneindene structure with substitution at the 3-position of the
25 indene ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
26 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
27 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
28 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
29 tetrahydropyranylmethyl group, whether or not further substituted in or
30 on any of the listed ring systems to any extent;
31 (F) Phenylacetylindoles: Any compound containing a 3-
-11-

LB475 LB475
2025 2025
1 phenylacetylindole structure with substitution at the nitrogen atom of
2 the indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
3 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
4 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
5 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
6 tetrahydropyranylmethyl group, whether or not further substituted in or
7 on any of the listed ring systems to any extent;
8 (G) Cyclohexylphenols: Any compound containing a 2-(3-
9 hydroxycyclohexyl)phenol structure with substitution at the 5-position of
10 the phenolic ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
11 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
12 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
13 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
14 tetrahydropyranylmethyl group, whether or not substituted in or on any of
15 the listed ring systems to any extent;
16 (H) Benzoylindoles: Any compound containing a 3-(benzoyl)indole
17 structure with substitution at the nitrogen atom of the indole ring by an
18 alkyl, haloalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl,
19 cycloalkylethyl, 2-(4-morpholinyl)ethyl group, cyanoalkyl, 1-(N-methyl-2-
20 piperidinyl)methyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
21 morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not
22 further substituted in or on any of the listed ring systems to any
23 extent;
24 (I) Adamantoylindoles: Any compound containing a 3-adamantoylindole
25 structure with substitution at the nitrogen atom of the indole ring by an
26 alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl, benzyl,
27 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl,
28 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
29 morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not
30 further substituted in or on any of the listed ring systems to any
31 extent;
-12-

LB475 LB475
2025 2025
1 (J) Tetramethylcyclopropanoylindoles: Any compound containing a 3-
2 tetramethylcyclopropanoylindole structure with substitution at the
3 nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl,
4 alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-
5 methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
6 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
7 tetrahydropyranylmethyl group, whether or not further substituted in or
8 on any of the listed ring systems to any extent;
9 (K) Indole carboxamides: Any compound containing a 1-indole-3-
10 carboxamide structure with substitution at the nitrogen atom of the
11 indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl,
12 benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-
13 piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
14 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
15 tetrahydropyranylmethyl group, substitution at the carboxamide group by
16 an alkyl, methoxy, benzyl, propionaldehyde, adamantyl, 1-naphthyl,
17 phenyl, aminooxoalkyl group, or quinolinyl group, whether or not further
18 substituted in or on any of the listed ring systems to any extent or to
19 the adamantyl, 1-mapthyl, phenyl, aminooxoalkyl, benzyl, or
20 propionaldehyde groups to any extent;
21 (L) Indole carboxylates: Any compound containing a 1-indole-3-
22 carboxylate structure with substitution at the nitrogen atom of the
23 indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl,
24 benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-
25 piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
26 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
27 tetrahydropyranylmethyl group, substitution at the carboxylate group by
28 an alkyl, methoxy, benzyl, propionaldehyde, adamantyl, 1-naphthyl,
29 phenyl, aminooxoalkyl group, or quinolinyl group, whether or not further
30 substituted in or on any of the listed ring systems to any extent or to
31 the adamantyl, 1-mapthyl, phenyl, aminooxoalkyl, benzyl, or
-13-

LB475 LB475
2025 2025
1 propionaldehyde groups to any extent; and
2 (M) Any nonnaturally occurring substance, chemical compound,
3 mixture, or preparation, not specifically listed elsewhere in these
4 schedules and which is not approved for human consumption by the federal
5 Food and Drug Administration, containing or constituting a cannabinoid
6 receptor agonist as defined in section 28-401;
7 (28) Zipeprol 1-methoxy-3-[4-(2-methoxy-2-phenylethyl)piperazin-1-
8 yl]-1-phenylpropan-2-ol, including its isomers, esters, ethers, salts,
9 and salts of isomers, esters, and ethers, whenever the existence of such
10 isomers, esters, ethers, and salts is possible within the specific
11 chemical designation;
12 (29) Any material, compound, mixture, or preparation containing any
13 quantity of a substituted phenethylamine as listed in subdivisions (A)
14 through (C) of this subdivision, unless specifically excepted, listed in
15 another schedule, or specifically named in this schedule, that is
16 structurally derived from phenylethan-2-amine by substitution on the
17 phenyl ring with a fused methylenedioxy ring, fused furan ring, or a
18 fused tetrahydrofuran ring; by substitution with two alkoxy groups; by
19 substitution with one alkoxy and either one fused furan, tetrahydrofuran,
20 or tetrahydropyran ring system; or by substitution with two fused ring
21 systems from any combination of the furan, tetrahydrofuran, or
22 tetrahydropyran ring systems, whether or not the compound is further
23 modified in any of the following ways:
24 (A) Substitution of the phenyl ring by any halo, hydroxyl, alkyl,
25 trifluoromethyl, alkoxy, or alkylthio groups; (B) substitution at the 2-
26 position by any alkyl groups; or (C) substitution at the 2-amino nitrogen
27 atom with alkyl, dialkyl, benzyl, hydroxybenzyl, or methoxybenzyl groups,
28 and including, but not limited to:
29 (i) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine, which is also known
30 as 2C-C or 2,5-Dimethoxy-4-chlorophenethylamine;
31 (ii) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine, which is also known
-14-

LB475 LB475
2025 2025
1 as 2C-D or 2,5-Dimethoxy-4-methylphenethylamine;
2 (iii) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine, which is also known
3 as 2C-E or 2,5-Dimethoxy-4-ethylphenethylamine;
4 (iv) 2-(2,5-Dimethoxyphenyl)ethanamine, which is also known as 2C-H
5 or 2,5-Dimethoxyphenethylamine;
6 (v) 2-(4-lodo-2,5-dimethoxyphenyl)ethanamine, which is also known as
7 2C-I or 2,5-Dimethoxy-4-iodophenethylamine;
8 (vi) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine, which is also known
9 as 2C-N or 2,5-Dimethoxy-4-nitrophenethylamine;
10 (vii) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine, which is also
11 known as 2C-P or 2,5-Dimethoxy-4-propylphenethylamine;
12 (viii) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine, which is
13 also known as 2C-T-2 or 2,5-Dimethoxy-4-ethylthiophenethylamine;
14 (ix) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine, which is
15 also known as 2C-T-4 or 2,5-Dimethoxy-4-isopropylthiophenethylamine;
16 (x) 2-(4-bromo-2,5-dimethoxyphenyl)ethanamine, which is also known
17 as 2C-B or 2,5-Dimethoxy-4-bromophenethylamine;
18 (xi) 2-(2,5-dimethoxy-4-(methylthio)phenyl)ethanamine, which is also
19 known as 2C-T or 4-methylthio-2,5-dimethoxyphenethylamine;
20 (xii) 1-(2,5-dimethoxy-4-iodophenyl)-propan-2-amine, which is also
21 known as DOI or 2,5-Dimethoxy-4-iodoamphetamine;
22 (xiii) 1-(4-Bromo-2,5-dimethoxyphenyl)-2-aminopropane, which is also
23 known as DOB or 2,5-Dimethoxy-4-bromoamphetamine;
24 (xiv) 1-(4-chloro-2,5-dimethoxy-phenyl)propan-2-amine, which is also
25 known as DOC or 2,5-Dimethoxy-4-chloroamphetamine;
26 (xv) 2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-
27 methoxyphenyl)methyl]ethanamine, which is also known as 2C-B-NBOMe; 25B-
28 NBOMe or 2,5-Dimethoxy-4-bromo-N-(2-methoxybenzyl)phenethylamine;
29 (xvi) 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-
30 methoxyphenyl)methyl]ethanamine, which is also known as 2C-I-NBOMe; 25I-
31 NBOMe or 2,5-Dimethoxy-4-iodo-N-(2-methoxybenzyl)phenethylamine;
-15-

LB475 LB475
2025 2025
1 (xvii) N-(2-Methoxybenzyl)-2-(3,4,5-trimethoxyphenyl)ethanamine,
2 which is also known as Mescaline-NBOMe or 3,4,5-trimethoxy-N-(2-
3 methoxybenzyl)phenethylamine;
4 (xviii) 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-
5 methoxyphenyl)methyl]ethanamine, which is also known as 2C-C-NBOMe; or
6 25C-NBOMe or 2,5-Dimethoxy-4-chloro-N-(2-methoxybenzyl)phenethylamine;
7 (xix) 2-(7-Bromo-5-methoxy-2,3-dihydro-1-benzofuran-4-yl)ethanamine,
8 which is also known as 2CB-5-hemiFLY;
9 (xx) 2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4-
10 yl)ethanamine, which is also known as 2C-B-FLY;
11 (xxi) 2-(10-Bromo-2,3,4,7,8,9-hexahydropyrano[2,3-g]chromen-5-
12 yl)ethanamine, which is also known as 2C-B-butterFLY;
13 (xxii) N-(2-Methoxybenzyl)-1-(8-bromo-2,3,6,7- tetrahydrobenzo[1,2-
14 b:4,5-b']difuran-4-yl)-2-aminoethane, which is also known as 2C-B-FLY-
15 NBOMe;
16 (xxiii) 1-(4-Bromofuro[2,3-f][1]benzofuran-8-yl)propan-2-amine,
17 which is also known as bromo-benzodifuranylisopropylamine or bromo-
18 dragonFLY;
19 (xxiv) N-(2-Hydroxybenzyl)-4-iodo-2,5-dimethoxyphenethylamine, which
20 is also known as 2C-INBOH or 25I-NBOH;
21 (xxv) 5-(2-Aminopropyl)benzofuran, which is also known as 5-APB;
22 (xxvi) 6-(2-Aminopropyl)benzofuran, which is also known as 6-APB;
23 (xxvii) 5-(2-Aminopropyl)-2,3-dihydrobenzofuran, which is also known
24 as 5-APDB;
25 (xxviii) 6-(2-Aminopropyl)-2,3-dihydrobenzofuran, which is also
26 known as 6-APDB;
27 (xxix) 2,5-dimethoxy-amphetamine, which is also known as 2, 5-
28 dimethoxy-a-methylphenethylamine; 2, 5-DMA;
29 (xxx) 2,5-dimethoxy-4-ethylamphetamine, which is also known as DOET;
30 (xxxi) 2,5-dimethoxy-4-(n)-propylthiophenethylamine, which is also
31 known as 2C-T-7;
-16-

LB475 LB475
2025 2025
1 (xxxii) 5-methoxy-3,4-methylenedioxy-amphetamine;
2 (xxxiii) 4-methyl-2,5-dimethoxy-amphetamine, which is also known as
3 4-methyl-2,5-dimethoxy-amethylphenethylamine; DOM and STP;
4 (xxxiv) 3,4-methylenedioxy amphetamine, which is also known as MDA;
5 (xxxv) 3,4-methylenedioxymethamphetamine, which is also known as
6 MDMA;
7 (xxxvi) 3,4-methylenedioxy-N-ethylamphetamine, which is also known
8 as N-ethyl-alpha-methyl-3,4(methylenedioxy)phenethylamine, MDE, MDEA;
9 (xxxvii) 3,4,5-trimethoxy amphetamine; and
10 (xxxviii) n-hydroxy-3, 4-Methylenedioxy-N-Hydroxyamphetamine, which
11 is also known as N-hydroxyMDA;
12 (30) Any material, compound, mixture, or preparation containing any
13 quantity of a substituted tryptamine unless specifically excepted, listed
14 in another schedule, or specifically named in this schedule, that is
15 structurally derived from 2-(1H-indol-3-yl)ethanamine, which is also
16 known as tryptamine, by mono- or di-substitution of the amine nitrogen
17 with alkyl or alkenyl groups or by inclusion of the amino nitrogen atom
18 in a cyclic structure whether or not the compound is further substituted
19 at the alpha position with an alkyl group or whether or not further
20 substituted on the indole ring to any extent with any alkyl, alkoxy,
21 halo, hydroxyl, or acetoxy groups, and including, but not limited to:
22 (A) 5-methoxy-N,N-diallyltryptamine, which is also known as 5-MeO-
23 DALT;
24 (B) 4-acetoxy-N,N-dimethyltryptamine, which is also known as 4-AcO-
25 DMT or OAcetylpsilocin;
26 (C) 4-hydroxy-N-methyl-N-ethyltryptamine, which is also known as 4-
27 HO-MET;
28 (D) 4-hydroxy-N,N-diisopropyltryptamine, which is also known as 4-
29 HO-DIPT;
30 (E) 5-methoxy-N-methyl-N-isopropyltryptamine, which is also known as
31 5-MeOMiPT;
-17-

LB475 LB475
2025 2025
1 (F) 5-Methoxy-N,N-Dimethyltryptamine, which is also known as 5-MeO-
2 DMT;
3 (G) 5-methoxy-N,N-diisopropyltryptamine, which is also known as 5-
4 MeO-DiPT;
5 (H) Diethyltryptamine, which is also known as N,N-Diethyltryptamine,
6 DET; and
7 (I) Dimethyltryptamine, which is also known as DMT; and
8 (31)(A) Any substance containing any quantity of the following
9 materials, compounds, mixtures, or structures:
10 (i) 3,4-methylenedioxymethcathinone, or bk-MDMA, or methylone;
11 (ii) 3,4-methylenedioxypyrovalerone, or MDPV;
12 (iii) 4-methylmethcathinone, or 4-MMC, or mephedrone;
13 (iv) 4-methoxymethcathinone, or bk-PMMA, or PMMC, or methedrone;
14 (v) Fluoromethcathinone, or FMC;
15 (vi) Naphthylpyrovalerone, or naphyrone; or
16 (vii) Beta-keto-N-methylbenzodioxolylpropylamine or bk-MBDB or
17 butylone; or
18 (B) Unless listed in another schedule, any substance which contains
19 any quantity of any material, compound, mixture, or structure, other than
20 bupropion, that is structurally derived by any means from 2-
21 aminopropan-1-one by substitution at the 1-position with either phenyl,
22 naphthyl, or thiophene ring systems, whether or not the compound is
23 further modified in any of the following ways:
24 (i) Substitution in the ring system to any extent with alkyl,
25 alkoxy, alkylenedioxy, haloalkyl, hydroxyl, or halide substituents,
26 whether or not further substituted in the ring system by one or more
27 other univalent substituents;
28 (ii) Substitution at the 3-position with an acyclic alkyl
29 substituent; or
30 (iii) Substitution at the 2-amino nitrogen atom with alkyl or
31 dialkyl groups, or by inclusion of the 2-amino nitrogen atom in a cyclic
-18-

LB475 LB475
2025 2025
1 structure.
2 (d) Unless specifically excepted or unless listed in another
3 schedule, any material, compound, mixture, or preparation which contains
4 any quantity of the following substances having a depressant effect on
5 the central nervous system, including its salts, isomers, and salts of
6 isomers whenever the existence of such salts, isomers, and salts of
7 isomers is possible within the specific chemical designation:
8 (1) Amineptine 7-[(10,11-dihydro-5H-dibenzo[a,d]-cyclohepten-5-
9 yl)amino]heptanoic acid, including its salts, isomers, and salts of
10 isomers;
11 (2) Mecloqualone;
12 (3) Methaqualone; and
13 (4) Gamma-Hydroxybutyric Acid. Some other names include: GHB; Gamma-
14 hydroxybutyrate; 4-Hydroxybutyrate; 4-Hydroxybutanoic Acid; Sodium
15 Oxybate; and Sodium Oxybutyrate.
16 (e) Unless specifically excepted or unless listed in another
17 schedule, any material, compound, mixture, or preparation which contains
18 any quantity of the following substances having a stimulant effect on the
19 central nervous system, including its salts, isomers, and salts of
20 isomers:
21 (1) Fenethylline;
22 (2) N-ethylamphetamine;
23 (3) Aminorex; aminoxaphen; 2-amino-5-phenyl-2-oxazoline; or 4,5-
24 dihydro-5-phenyl-2-oxazolamine;
25 (4) Cathinone; 2-amino-1-phenyl-1-propanone; alpha-
26 aminopropiophenone; 2-aminopropiophenone; and norephedrone;
27 (5) Methcathinone, its salts, optical isomers, and salts of optical
28 isomers. Some other names: 2-(methylamino)-propiophenone; alpha-
29 (methylamino)propiophenone; 2-(methylamino)-1-phenylpropan-1-one; alpha-
30 N-methylaminopropiophenone; methylcathinone; monomethylpropion;
31 ephedrone; N-methylcathinone; AL-464; AL-422; AL-463; UR1432; and 4-MEC;
-19-

LB475 LB475
2025 2025
1 (6) (+/-)cis-4-methylaminorex; and (+/-)cis-4,5-dihydro-4-methyl-5-
2 phenyl-2-oxazolamine;
3 (7) N,N-dimethylamphetamine; N,N-alpha-trimethyl-benzeneethanamine;
4 and N,N-alpha-trimethylphenethylamine;
5 (8) Benzylpiperazine, 1-benzylpiperazine;
6 (9) 4,4'-dimethylaminorex (other names: 4,4'-DMAR, 4,5-dihydro-4-
7 methyl-5-(4-methylphenyl)-2-oxazolamine); and
8 (10) N-phenyl-N' -(3-(1- phenylpropan-2-yl)-1,2,3-oxadiazol-3-
9 ium-5-yl)carbamimidate), including its salts, isomers, and salts of
10 isomers.
11 (f) Any controlled substance analogue to the extent intended for
12 human consumption.
13 Schedule II
14 (a) Any of the following substances except those narcotic drugs
15 listed in other schedules whether produced directly or indirectly by
16 extraction from substances of vegetable origin, independently by means of
17 chemical synthesis, or by combination of extraction and chemical
18 synthesis:
19 (1) Opium and opiate, and any salt, compound, derivative, or
20 preparation of opium or opiate, excluding apomorphine, buprenorphine,
21 thebaine-derived butorphanol, dextrorphan, nalbuphine, nalmefene,
22 naloxone, and naltrexone and their salts, but including the following:
23 (A) Raw opium;
24 (B) Opium extracts;
25 (C) Opium fluid;
26 (D) Powdered opium;
27 (E) Granulated opium;
28 (F) Tincture of opium;
29 (G) Codeine;
30 (H) Ethylmorphine;
31 (I) Etorphine hydrochloride;
-20-

LB475 LB475
2025 2025
1 (J) Hydrocodone;
2 (K) Hydromorphone;
3 (L) Metopon;
4 (M) Morphine;
5 (N) Oxycodone;
6 (O) Oxymorphone;
7 (P) Oripavine;
8 (Q) Thebaine; and
9 (R) Dihydroetorphine;
10 (2) Any salt, compound, derivative, or preparation thereof which is
11 chemically equivalent to or identical with any of the substances referred
12 to in subdivision (1) of this subdivision, except that these substances
13 shall not include the isoquinoline alkaloids of opium;
14 (3) Opium poppy and poppy straw;
15 (4) Coca leaves and any salt, compound, derivative, or preparation
16 of coca leaves, and any salt, compound, derivative, or preparation
17 thereof which is chemically equivalent to or identical with any of these
18 substances, including cocaine or ecgonine and its salts, optical isomers,
19 and salts of optical isomers, except that the substances shall not
20 include decocainized coca leaves or extractions which do not contain
21 cocaine or ecgonine; and
22 (5) Concentrate of poppy straw, the crude extract of poppy straw in
23 either liquid, solid, or powder form which contains the phenanthrene
24 alkaloids of the opium poppy.
25 (b) Unless specifically excepted or unless in another schedule any
26 of the following opiates, including their isomers, esters, ethers, salts,
27 and salts of their isomers, esters, and ethers whenever the existence of
28 such isomers, esters, ethers, and salts is possible within the specific
29 chemical designation, dextrorphan excepted:
30 (1) Alphaprodine;
31 (2) Anileridine;
-21-

LB475 LB475
2025 2025
1 (3) Bezitramide;
2 (4) Diphenoxylate;
3 (5) Fentanyl;
4 (6) Isomethadone;
5 (7) Levomethorphan;
6 (8) Levorphanol;
7 (9) Metazocine;
8 (10) Methadone;
9 (11) Methadone-intermediate, 4-cyano-2-dimethylamino-4,4-diphenyl
10 butane;
11 (12) Moramide-intermediate, 2-methyl-3-morpholino-1,1-
12 diphenylpropane-carboxylic acid;
13 (13) Norfentanyl (N-phenyl-N-piperidin-4-yl) propionamide;
14 (14) Oliceridine;
15 (15) Pethidine or meperidine;
16 (16) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;
17 (17) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-
18 carboxylate;
19 (18) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-
20 carboxylic acid;
21 (19) Phenazocine;
22 (20) Piminodine;
23 (21) Racemethorphan;
24 (22) Racemorphan;
25 (23) Dihydrocodeine;
26 (24) Bulk Propoxyphene in nondosage forms;
27 (25) Sufentanil;
28 (26) Alfentanil;
29 (27) Levo-alphacetylmethadol which is also known as levo-alpha-
30 acetylmethadol, levomethadyl acetate, and LAAM;
31 (28) Carfentanil;
-22-

LB475 LB475
2025 2025
1 (29) Remifentanil;
2 (30) Tapentadol; and
3 (31) Thiafentanil.
4 (c) Any material, compound, mixture, or preparation which contains
5 any quantity of the following substances having a potential for abuse
6 associated with a stimulant effect on the central nervous system:
7 (1) Amphetamine, its salts, optical isomers, and salts of its
8 optical isomers;
9 (2) Phenmetrazine and its salts;
10 (3) Methamphetamine, its salts, isomers, and salts of its isomers;
11 (4) Methylphenidate; and
12 (5) Lisdexamfetamine, its salts, isomers, and salts of its isomers.
13 (d) Any material, compound, mixture, or preparation which contains
14 any quantity of the following substances having a potential for abuse
15 associated with a depressant effect on the central nervous system,
16 including their salts, isomers, and salts of isomers whenever the
17 existence of such salts, isomers, and salts of isomers is possible within
18 the specific chemical designations:
19 (1) Amobarbital;
20 (2) Secobarbital;
21 (3) Pentobarbital;
22 (4) Phencyclidine; and
23 (5) Glutethimide.
24 (e) Hallucinogenic substances known as:
25 (1) Nabilone. Another name for nabilone: (+/-)-trans-3-(1,1-
26 dimethylheptyl)- 6,6a,7,8,10,10a-Hexahydro-1-hydroxy-6,6-dimethyl-9H-
27 dibenzo(b,d)pyran-9-one; and
28 (2) Dronabinol in an oral solution in a drug product approved by the
29 federal Food and Drug Administration.
30 (f) Unless specifically excepted or unless listed in another
31 schedule, any material, compound, mixture, or preparation which contains
-23-

LB475 LB475
2025 2025
1 any quantity of the following substances:
2 (1) Immediate precursor to amphetamine and methamphetamine:
3 Phenylacetone. Trade and other names shall include, but are not limited
4 to: Phenyl-2-propanone; P2P; benzyl methyl ketone; and methyl benzyl
5 ketone;
6 (2) Immediate precursors to phencyclidine, PCP:
7 (A) 1-phenylcyclohexylamine; or
8 (B) 1-piperidinocyclohexanecarbonitrile, PCC; or
9 (3) Immediate precursor to fentanyl; 4-anilino-N-phenethylpiperidine
10 (ANPP).
11 Schedule III
12 (a) Any material, compound, mixture, or preparation which contains
13 any quantity of the following substances having a potential for abuse
14 associated with a stimulant effect on the central nervous system,
15 including their salts, isomers, whether optical, position, or geometric,
16 and salts of such isomers whenever the existence of such salts, isomers,
17 and salts of isomers is possible within the specific chemical
18 designation:
19 (1) Benzphetamine;
20 (2) Chlorphentermine;
21 (3) Clortermine; and
22 (4) Phendimetrazine.
23 (b) Any material, compound, mixture, or preparation which contains
24 any quantity of the following substances having a potential for abuse
25 associated with a depressant effect on the central nervous system:
26 (1) Any substance which contains any quantity of a derivative of
27 barbituric acid or any salt of a derivative of barbituric acid, except
28 those substances which are specifically listed in other schedules of this
29 section;
30 (2) Aprobarbital;
31 (3) Butabarbital;
-24-

LB475 LB475
2025 2025
1 (4) Butalbital;
2 (5) Butethal;
3 (6) Butobarbital;
4 (7) Chlorhexadol;
5 (8) Embutramide;
6 (9) Lysergic acid;
7 (10) Lysergic acid amide;
8 (11) Methyprylon;
9 (12) Perampanel;
10 (13) Secbutabarbital;
11 (14) Sulfondiethylmethane;
12 (15) Sulfonethylmethane;
13 (16) Sulfonmethane;
14 (17) Nalorphine;
15 (18) Talbutal;
16 (19) Thiamylal;
17 (20) Thiopental;
18 (21) Vinbarbital;
19 (22) Any compound, mixture, or preparation containing amobarbital,
20 secobarbital, pentobarbital, or any salt thereof and one or more other
21 active medicinal ingredients which are not listed in any schedule;
22 (23) Any suppository dosage form containing amobarbital,
23 secobarbital, pentobarbital, or any salt of any of these drugs and
24 approved by the federal Food and Drug Administration for marketing only
25 as a suppository;
26 (24) Any drug product containing gamma-hydroxybutyric acid,
27 including its salts, isomers, and salts of isomers, for which an
28 application is approved under section 505 of the Federal Food, Drug, and
29 Cosmetic Act, 21 U.S.C. 355, as such section existed on January 1, 2014;
30 (25) Ketamine, its salts, isomers, and salts of isomers. Some other
31 names for ketamine: (+/-)-2-(2-chlorophenyl)-2-(methylamino)-
-25-

LB475 LB475
2025 2025
1 cyclohexanone; and
2 (26) Tiletamine and zolazepam or any salt thereof. Trade or other
3 names for a tiletamine-zolazepam combination product shall include, but
4 are not limited to: telazol. Trade or other names for tiletamine shall
5 include, but are not limited to: 2-(ethylamino)-2-(2-thienyl)-
6 cyclohexanone. Trade or other names for zolazepam shall include, but are
7 not limited to: 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-
8 trimethylpyrazolo-(3,4-e) (1,4)-diazepin-7(1H)-one, and flupyrazapon.
9 (c) Unless specifically excepted or unless listed in another
10 schedule:
11 (1) Any material, compound, mixture, or preparation containing
12 limited quantities of any of the following narcotic drugs, or any salts
13 calculated as the free anhydrous base or alkaloid, in limited quantities
14 as set forth below:
15 (A) Not more than one and eight-tenths grams of codeine per one
16 hundred milliliters or not more than ninety milligrams per dosage unit,
17 with an equal or greater quantity of an isoquinoline alkaloid of opium;
18 (B) Not more than one and eight-tenths grams of codeine per one
19 hundred milliliters or not more than ninety milligrams per dosage unit,
20 with one or more active, nonnarcotic ingredients in recognized
21 therapeutic amounts;
22 (C) Not more than one and eight-tenths grams of dihydrocodeine per
23 one hundred milliliters or not more than ninety milligrams per dosage
24 unit, with one or more active, nonnarcotic ingredients in recognized
25 therapeutic amounts;
26 (D) Not more than three hundred milligrams of ethylmorphine per one
27 hundred milliliters or not more than fifteen milligrams per dosage unit,
28 with one or more active, nonnarcotic ingredients in recognized
29 therapeutic amounts;
30 (E) Not more than five hundred milligrams of opium per one hundred
31 milliliters or per one hundred grams, or not more than twenty-five
-26-

LB475 LB475
2025 2025
1 milligrams per dosage unit, with one or more active, nonnarcotic
2 ingredients in recognized therapeutic amounts; and
3 (F) Not more than fifty milligrams of morphine per one hundred
4 milliliters or per one hundred grams with one or more active, nonnarcotic
5 ingredients in recognized therapeutic amounts; and
6 (2) Any material, compound, mixture, or preparation containing any
7 of the following narcotic drug or its salts, as set forth below:
8 (A) Buprenorphine.
9 (d) Unless contained on the list of exempt anabolic steroids of the
10 Drug Enforcement Administration of the United States Department of
11 Justice as the list existed on January 31, 2022, any anabolic steroid,
12 which shall include any material, compound, mixture, or preparation
13 containing any quantity of the following substances, including its salts,
14 isomers, and salts of isomers whenever the existence of such salts of
15 isomers is possible within the specific chemical designation:
16 (1) 3-beta,17-dihydroxy-5a-androstane;
17 (2) 3-alpha,17-beta-dihydroxy-5a-androstane;
18 (3) 5-alpha-androstan-3,17-dione;
19 (4) 1-androstenediol (3-beta,17-beta-dihydroxy-5-alpha-androst-1-
20 ene);
21 (5) 1-androstenediol (3-alpha,17-beta-dihydroxy-5-alpha-androst-1-
22 ene);
23 (6) 4-androstenediol (3-beta,17-beta-dihydroxy-androst-5-ene);
24 (7) 5-androstenediol (3-beta,17-beta-dihydroxy-androst-5-ene);
25 (8) 1-androstenedione ([5-alpha]-androst-1-en-3,17-dione);
26 (9) 4-androstenedione (androst-4-en-3,17-dione);
27 (10) 5-androstenedione (androst-5-en-3,17-dione);
28 (11) Bolasterone (7-alpha,17-alpha-dimethyl-17-beta-
29 hydroxyandrost-4-en-3-one);
30 (12) Boldenone (17-beta-hydroxyandrost-1,4-diene-3-one);
31 (13) Boldione (androsta-1,4-diene-3,17-3-one);
-27-

LB475 LB475
2025 2025
1 (14) Calusterone (7-beta,17-alpha-dimethyl-17-beta-hydroxyandrost-4-
2 en-3-one);
3 (15) Clostebol (4-chloro-17-beta-hydroxyandrost-4-en-3-one);
4 (16) Dehydrochloromethyltestosterone (4-chloro-17-beta-hydroxy-17-
5 alpha-methyl-androst-1,4-dien-3-one);
6 (17) Desoxymethyltestosterone (17-alpha-methyl-5-alpha-androst-2-
7 en-17-beta-ol) (a.k.a. 'madol');
8 (18) Delta-1-Dihydrotestosterone (a.k.a. '1-testosterone')(17-beta-
9 hydroxy-5-alpha-androst-1-en-3-one);
10 (19) 4-Dihydrotestosterone (17-beta-hydroxy-androstan-3-one);
11 (20) Drostanolone (17-beta-hydroxy-2-alpha-methyl-5-alpha-
12 androstan-3-one);
13 (21) Ethylestrenol (17-alpha-ethyl-17-beta-hydroxyestr-4-ene);
14 (22) Fluoxymesterone (9-fluoro-17-alpha-methyl-11-beta,17-beta-
15 dihydroxyandrost-4-en-3-one);
16 (23) Formebulone (formebolone); (2-formyl-17-alpha-methyl-11-
17 alpha,17-beta-dihydroxyandrost-1,4-dien-3-one);
18 (24) Furazabol (17-alpha-methyl-17-beta-hydroxyandrostano[2,3-c]-
19 furazan);
20 (25) 13-beta-ethyl-17-beta-hydroxygon-4-en-3-one;
21 (26) 4-hydroxytestosterone (4,17-beta-dihydroxy-androst-4-en-3-one);
22 (27) 4-hydroxy-19-nortestosterone (4,17-beta-dihydroxy-estr-4-en-3-
23 one);
24 (28) Mestanolone (17-alpha-methyl-17-beta-hydroxy-5-androstan-3-
25 one);
26 (29) Mesterolone (17-alpha-methyl-17-beta-hydroxy-5-androstan-3-
27 one);
28 (30) Methandienone (17-alpha-methyl-17-beta-hydroxyandrost-1,4-
29 dien-3-one);
30 (31) Methandriol (17-alpha-methyl-3-beta,17-beta-dihydroxyandrost-5-
31 ene);
-28-

LB475 LB475
2025 2025
1 (32) Methasterone (2-alpha,17-alpha-dimethyl-5-alpha-androstan-17-
2 beta-ol-3-one);
3 (33) Methenolone (1-methyl-17-beta-hydroxy-5-alpha-androst-1-en-3-
4 one);
5 (34) 17-alpha-methyl-3-beta,17-beta-dihydroxy-5a-androstane;
6 (35) 17-alpha-methyl-3-alpha,17-beta-dihydroxy-5a-androstane;
7 (36) 17-alpha-methyl-3-beta,17-beta-dihydroxyandrost-4-ene;
8 (37) 17-alpha-methyl-4-hydroxynandrolone (17-alpha-methyl-4-
9 hydroxy-17-beta-hydroxyestr-4-en-3-one);
10 (38) Methyldienolone (17-alpha-methyl-17-beta-hydroxyestra-4,9(10)-
11 dien-3-one);
12 (39) Methyltrienolone (17-alpha-methyl-17-beta-hydroxyestra-4,9,11-
13 trien-3-one);
14 (40) Methyltestosterone (17-alpha-methyl-17-beta-hydroxyandrost-4-
15 en-3-one);
16 (41) Mibolerone (7-alpha,17-alpha-dimethyl-17-beta-hydroxyestr-4-
17 en-3-one);
18 (42) 17-alpha-methyl-delta-1-dihydrotestosterone (17-beta-
19 hydroxy-17-alpha-methyl-5-alpha-androst-1-en-3-one) (a.k.a. '17-alpha-
20 methyl-1-testosterone');
21 (43) Nandrolone (17-beta-hydroxyestr-4-en-3-one);
22 (44) 19-nor-4-androstenediol (3-beta, 17-beta-dihydroxyestr-4-ene);
23 (45) 19-nor-4-androstenediol (3-alpha, 17-beta-dihydroxyestr-4-ene);
24 (46) 19-nor-5-androstenediol (3-beta, 17-beta-dihydroxyestr-5-ene);
25 (47) 19-nor-5-androstenediol (3-alpha, 17-beta-dihydroxyestr-5-ene);
26 (48) 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-
27 dione);
28 (49) 19-nor-4-androstenedione (estr-4-en-3,17-dione);
29 (50) 19-nor-5-androstenedione (estr-5-en-3,17-dione);
30 (51) Norbolethone (13-beta, 17-alpha-diethyl-17-beta-hydroxygon-4-
31 en-3-one);
-29-

LB475 LB475
2025 2025
1 (52) Norclostebol (4-chloro-17-beta-hydroxyestr-4-en-3-one);
2 (53) Norethandrolone (17-alpha-ethyl-17-beta-hydroxyestr-4-en-3-
3 one);
4 (54) Normethandrolone (17-alpha-methyl-17-beta-hydroxyestr-4-en-3-
5 one);
6 (55) Oxandrolone (17-alpha-methyl-17-beta-hydroxy-2-oxa-[5-alpha]-
7 androstan-3-one);
8 (56) Oxymesterone (17-alpha-methyl-4,17-beta-dihydroxyandrost-4-
9 en-3-one);
10 (57) Oxymetholone (17-alpha-methyl-2-hydroxymethylene-17-beta-
11 hydroxy-[5-alpha]-androstan-3-one);
12 (58) Prostanozol (17-beta-hydroxy-5-alpha-androstano[3,2-
13 c]pyrazole);
14 (59) Stanozolol (17-alpha-methyl-17-beta-hydroxy-[5-alpha]-
15 androst-2-eno[3,2-c]-pyrazole);
16 (60) Stenbolone (17-beta-hydroxy-2-methyl-[5-alpha]-androst-1-en-3-
17 one);
18 (61) Testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-
19 oic acid lactone);
20 (62) Testosterone (17-beta-hydroxyandrost-4-en-3-one);
21 (63) Tetrahydrogestrinone (13-beta, 17-alpha-diethyl-17-beta-
22 hydroxygon-4,9,11-trien-3-one);
23 (64) Trenbolone (17-beta-hydroxyestr-4,9,11-trien-3-one);
24 (65) [3,2-c]-furazan-5 alpha-androstane-17 beta-ol;
25 (66) [3,2-c]pyrazole-androst-4-en-17 beta-ol;
26 (67) 17 alpha-methyl-androst-ene-3,17 beta-diol;
27 (68) 17 alpha-methyl-androsta-1,4-diene-3,17 beta-diol;
28 (69) 17 alpha-methyl-androstan-3-hydroxyimine-17 beta-ol;
29 (70) 17 beta-hydroxy-androstano[2,3-d]isoxazole;
30 (71) 17 beta-hydroxy-androstano[3,2-c]isoxazole;
31 (72) 18a-homo-3-hydroxy-estra-2,5(10)-dien-17-one;
-30-

LB475 LB475
2025 2025
1 (73) 2 alpha, 3 alpha-epithio-17 alpha-methyl-5 alpha-androstan-17
2 beta-ol;
3 (74) 4-chloro-17 alpha-methyl-17 beta-hydroxy-androst-4-en-3-one;
4 (75) 4-chloro-17 alpha-methyl-17 beta-hydroxy-androst-4-en-3,11-
5 dione;
6 (76) 4-chloro-17 alpha-methyl-androst-4-ene-3 beta,17 beta-diol;
7 (77) 4-chloro-17 alpha-methyl-androsta-1,4-diene-3,17 beta-diol;
8 (78) 4-hydroxy-androst-4-ene-3,17-dione;
9 (79) 5 alpha-Androstan-3,6,17-trione;
10 (80) 6-bromo-androst-1,4-diene-3,17-dione;
11 (81) 6-bromo-androstan-3,17-dione;
12 (82) 6 alpha-methyl-androst-4-ene-3,17-dione;
13 (83) Delta 1-dihydrotestosterone;
14 (84) Estra-4,9,11-triene-3,17-dione; and
15 (85) Any salt, ester, or ether of a drug or substance described or
16 listed in this subdivision if the salt, ester, or ether promotes muscle
17 growth.
18 (e) Hallucinogenic substances known as:
19 (1) Dronabinol, synthetic, in sesame oil and encapsulated in a soft
20 gelatin capsule in a drug product approved by the federal Food and Drug
21 Administration. Some other names for dronabinol are (6aR-
22 trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo
23 (b,d)pyran-1-ol or (-)-delta-9-(trans)-tetrahydrocannabinol.
24 Schedule IV
25 (a) Any material, compound, mixture, or preparation which contains
26 any quantity of the following substances, including their salts, isomers,
27 and salts of isomers whenever the existence of such salts, isomers, and
28 salts of isomers is possible within the specific chemical designation:
29 (1) Barbital;
30 (2) Chloral betaine;
31 (3) Chloral hydrate;
-31-

LB475 LB475
2025 2025
1 (4) Chlordiazepoxide, but not including librax (chlordiazepoxide
2 hydrochloride and clindinium bromide) or menrium (chlordiazepoxide and
3 water soluble esterified estrogens);
4 (5) Clonazepam;
5 (6) Clorazepate;
6 (7) Daridorexant;
7 (8) Diazepam;
8 (9) Ethchlorvynol;
9 (10) Ethinamate;
10 (11) Flurazepam;
11 (12) Mebutamate;
12 (13) Meprobamate;
13 (14) Methohexital;
14 (15) Methylphenobarbital;
15 (16) Oxazepam;
16 (17) Paraldehyde;
17 (18) Petrichloral;
18 (19) Phenobarbital;
19 (20) Prazepam;
20 (21) Alprazolam;
21 (22) Bromazepam;
22 (23) Camazepam;
23 (24) Clobazam;
24 (25) Clotiazepam;
25 (26) Cloxazolam;
26 (27) Delorazepam;
27 (28) Estazolam;
28 (29) Ethyl loflazepate;
29 (30) Fludiazepam;
30 (31) Flunitrazepam;
31 (32) Halazepam;
-32-

LB475 LB475
2025 2025
1 (33) Haloxazolam;
2 (34) Ketazolam;
3 (35) Loprazolam;
4 (36) Lorazepam;
5 (37) Lormetazepam;
6 (38) Medazepam;
7 (39) Nimetazepam;
8 (40) Nitrazepam;
9 (41) Nordiazepam;
10 (42) Oxazolam;
11 (43) Pinazepam;
12 (44) Temazepam;
13 (45) Tetrazepam;
14 (46) Triazolam;
15 (47) Midazolam;
16 (48) Quazepam;
17 (49) Zolpidem;
18 (50) Dichloralphenazone;
19 (51) Zaleplon;
20 (52) Zopiclone;
21 (53) Fospropofol;
22 (54) Alfaxalone;
23 (55) Suvorexant;
24 (56) Carisoprodol;
25 (57) Brexanolone; 3 alpha-hydroxy-5 alpha-pregnan-20-one;
26 (58) Lemborexant;
27 (59) Solriamfetol; 2-amino-3-phenylpropyl carbamate;
28 (60) Remimazolam; and
29 (61) Serdexmethylphenidate; and .
30 (62) Tianeptine.
31 (b) Any material, compound, mixture, or preparation which contains
-33-

LB475 LB475
2025 2025
1 any quantity of the following substance, including its salts, isomers,
2 whether optical, position, or geometric, and salts of such isomers,
3 whenever the existence of such salts, isomers, and salts of isomers is
4 possible: Fenfluramine.
5 (c) Unless specifically excepted or unless listed in another
6 schedule, any material, compound, mixture, or preparation which contains
7 any quantity of the following substances having a stimulant effect on the
8 central nervous system, including their salts, isomers, whether optical,
9 position, or geometric, and salts of such isomers whenever the existence
10 of such salts, isomers, and salts of isomers is possible within the
11 specific chemical designation:
12 (1) Diethylpropion;
13 (2) Phentermine;
14 (3) Pemoline, including organometallic complexes and chelates
15 thereof;
16 (4) Mazindol;
17 (5) Pipradrol;
18 (6) SPA, ((-)-1-dimethylamino-1,2-diphenylethane);
19 (7) Cathine. Another name for cathine is ((+)-norpseudoephedrine);
20 (8) Fencamfamin;
21 (9) Fenproporex;
22 (10) Mefenorex;
23 (11) Modafinil; and
24 (12) Sibutramine.
25 (d) Unless specifically excepted or unless listed in another
26 schedule, any material, compound, mixture, or preparation which contains
27 any quantity of the following narcotic drugs, or their salts or isomers
28 calculated as the free anhydrous base or alkaloid, in limited quantities
29 as set forth below:
30 (1) Propoxyphene in manufactured dosage forms;
31 (2) Not more than one milligram of difenoxin and not less than
-34-

LB475 LB475
2025 2025
1 twenty-five micrograms of atropine sulfate per dosage unit; and
2 (3) 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its
3 salts, optical and geometric isomers, and salts of these isomers to
4 include: Tramadol.
5 (e) Unless specifically excepted or unless listed in another
6 schedule, any material, compound, mixture, or preparation which contains
7 any quantity of the following substances substance, including their its
8 salts:
9 (1) Pentazocine; and
10 (2) Butorphanol (including its optical isomers).
11 (f) Any material, compound, mixture, or preparation which contains
12 any quantity of the following substance substances, including its salts,
13 isomers, and salts of such isomers, whenever the existence of such salts,
14 isomers, and salts of isomers is possible: Lorcaserin.
15 (g)(1) Unless specifically excepted or unless listed in another
16 schedule, any material, compound, mixture, or preparation which contains
17 any quantity of the following substance, including its salts, optical
18 isomers, and salts of such optical isomers: Ephedrine.
19 (2) The following drug products containing ephedrine, its salts,
20 optical isomers, and salts of such optical isomers, are excepted from
21 subdivision (g)(1) of Schedule IV if they (A) are stored behind a
22 counter, in an area not accessible to customers, or in a locked case so
23 that a customer needs assistance from an employee to access the drug
24 product; (B) are sold by a person, eighteen years of age or older, in the
25 course of his or her employment to a customer eighteen years of age or
26 older with the following restrictions: No customer shall be allowed to
27 purchase, receive, or otherwise acquire more than three and six-tenths
28 grams of ephedrine base during a twenty-four-hour period; no customer
29 shall purchase, receive, or otherwise acquire more than nine grams of
30 ephedrine base during a thirty-day period; and the customer shall display
31 a valid driver's or operator's license, a Nebraska state identification
-35-

LB475 LB475
2025 2025
1 card, a military identification card, an alien registration card, or a
2 passport as proof of identification; (C) are labeled and marketed in a
3 manner consistent with the pertinent OTC Tentative Final or Final
4 Monograph; (D) are manufactured and distributed for legitimate medicinal
5 use in a manner that reduces or eliminates the likelihood of abuse; and
6 (E) are not marketed, advertised, or represented in any manner for the
7 indication of stimulation, mental alertness, euphoria, ecstasy, a buzz or
8 high, heightened sexual performance, or increased muscle mass:
9 (i) Primatene Tablets; and
10 (ii) Bronkaid Dual Action Caplets.
11 Schedule V
12 (a) Any compound, mixture, or preparation containing any of the
13 following limited quantities of narcotic drugs or salts calculated as the
14 free anhydrous base or alkaloid, which shall include one or more
15 nonnarcotic active medicinal ingredients in sufficient proportion to
16 confer upon the compound, mixture, or preparation valuable medicinal
17 qualities other than those possessed by the narcotic drug alone:
18 (1) Not more than two hundred milligrams of codeine per one hundred
19 milliliters or per one hundred grams;
20 (2) Not more than one hundred milligrams of dihydrocodeine per one
21 hundred milliliters or per one hundred grams;
22 (3) Not more than one hundred milligrams of ethylmorphine per one
23 hundred milliliters or per one hundred grams;
24 (4) Not more than two and five-tenths milligrams of diphenoxylate
25 and not less than twenty-five micrograms of atropine sulfate per dosage
26 unit;
27 (5) Not more than one hundred milligrams of opium per one hundred
28 milliliters or per one hundred grams; and
29 (6) Not more than five-tenths milligram of difenoxin and not less
30 than twenty-five micrograms of atropine sulfate per dosage unit.
31 (b) Unless specifically exempted or excluded or unless listed in
-36-

LB475 LB475
2025 2025
1 another schedule, any material, compound, mixture, or preparation which
2 contains any quantity of the following substances having a stimulant
3 effect on the central nervous system, including its salts, isomers, and
4 salts of isomers: Pyrovalerone.
5 (c) Unless specifically exempted or excluded or unless listed in
6 another schedule, any material, compound, mixture, or preparation which
7 contains any quantity of the following substances having a depressant
8 effect on the central nervous system, including its salts, isomers, and
9 salts of isomers:
10 (1) Ezogabine (N-(2-amino-4-(4-fluorobenzylamino)-phenyl)-carbamic
11 acid ethyl ester);
12 (2) Ganaxolone;
13 (3) Lacosamide ((R)-2-acetoamido-N-benzyl-3-methoxy-propionamide);
14 (4) Pregabalin ((S)-3-(aminomethyl)-5-methylhexanoic acid);
15 (5) Brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]
16 butanamide) (also referred to as BRV; UCB-34714; Briviact), including its
17 salts;
18 (6) Cenobamate; and
19 (7) Lasmiditan.
20 Sec. 2. Original section 28-405, Revised Statutes Cumulative
21 Supplement, 2024, is repealed.
-37-

[DELETED: yRAs 2 R S C S 2 tc t a a c s a t r toB5L52]
[DELETED: S 1 S 2 R S C S22 T f a t s o c src o t l o e p o t D EA o t U S D o J a t leS(0e s a s o i e a e u1s e w t e o s i e2e3(4(5(6k7(8(9(0(1(2(3(4(5(6(7(8(9(0(1(5L52]
[DELETED: (((((((((0(1(2(3(4(5(6(7(8(9(0(1(2(3(4(5(6( A N7p p 18p9(0(1p5L52]
[DELETED: i( 1 ( i oi( P 1 io( A Npi( A N0p i o i s a s1o2( B N3i4( B N5p i o i s a s6o7( B ( n N8p i o a9g0( 3 N1p i o a g i2s3( N4(5( T N6p7( P N8p i o i s a s o9i0( U 31m5L52]
[DELETED: (((( A 3 4 cb((((0(1(2(3(4(5(6y7(8(9(0(1(2(3(4(5(6(7(8(9(0(1(5L52]
[DELETED: ((((((( B ( n 1 ep( F s t i e e0s a s o i e a e U s1e l i a s o s n i t2s t i a s t i s r t3f4(5m6(7a8(9a0( R o t a r w a a m1w2(3( A o t f o d t s i4a s o i u s e w t5e6t7(8(9(0(1(5L52]
[DELETED: (((((((((0(1(2(3(4(5(6(7(8(9(0a q o t f h s t s1i2e3t4o5( B T a o n s i b a n6l t 3 37d N 58d9( 4 T a o n s0i b a n l t 41m5L52]
[DELETED: (a n l t 4 ap( 4 T a o n si b a n l t 4m( P T a o n si b a n l t 1a0( I T a o n s i b a n1l t 72m ( a ( i a T3i4(5(6(7(8( P P s m a p o t p p9c0o1e2o3(4(5(6e7e o c s o s s d a8t i w s c s a p9a0a t o i e d i a d p1a b t f F a D A D 6 c o5L52]
[DELETED: too t s i n i s c ot s s b i r o t ndiF((0(1i223(4( P T a o n s i b a n5l t 36d7(8i b a n l t N (9p N0c1( P a o p T a o n2s i b a n l t 13p4(5M a 3 i6a7(8(9(0( S d o S A S d o1S A i a p o t p p c5L52]
[DELETED: b a S d w g o n t st a e f a p o s p a e cm d m o p o s p iswp(q( t ( o t s i t s i0s1u s e e i t s S2n o t s p c i n3i4o c o t s s b i u t5s6p7m o s t o a t t s c8p9( T M t n0c1s2r e o c s a s s3d a t i w s c s a4p a s a t f D 1 c o t5t a t o i D 6 c o t6t7t8i9F0( N A c c a 31n5L52]
[DELETED: i r b a a h a h bc c 2 gc 1 1p 1 oto( N A c c a 1 Hyo0c c 2 g1c 1 12p 1 o3t4o5( N A c c a 36n7p r b a a h a h b8c c 2 g9c 1 10p 1 o1t2o3( N A c c 4n5i r b a a h a h b6c c 2 g7c 1 18p 1 o9t0o1( P A c c a 35L52]
[DELETED: p s w s a t n a ot i r b a a h a h bc c 2 gc 1 1p 1 oto( C A c c a 2h0t p r b a a h a h b1c c 2 g2c 1 13p 1 o4t5t6( B A c c a 37s8a h a h b c9c0p 1 11m o t g w o n2f s i o o a o t l r s t a3e4(5s6a h c a h b7c c 1829m o t g w o n0f s i o o a o t l r s t a1e5L52]
[DELETED: ( T A c c a 3t s w s a tn a o t i r b a a h ca h b c c 1m 2 1p 1 oto( I c A c c a 10c s w s a t n a o t1i r b a a h c a h2b c c 13p 2 14p 1 o5t6a a m b p a 17p8s9t a 1 p a b o0p1( I c A c c a 12c s w s a t n a o t3i r b a a h c a h4b c c 15p 2 16p 1 o7t8a a m b p a 19p0s1t a 1 p a b o5L52]
[DELETED: p( A n o s c cm o p n s l e i tsF a D A c o c a cr( Z 1y i i i e e sa0i e e a s i p w t s1c2(3q o a s p a l i s (4t5a s o s n i t s t i6s d f p b s o t7p r w a f m r f f r o 8f t r b s w t a g b9s0o1s f a c o t f t o2t r s w o n t c i f3m4( S o t p r b a h h a5t6p7a8a9(0a1(5L52]
[DELETED: a(a(o(2(a0( 2 w i a1k2( 2 w i3a4( 2 w i5a6( 2 w i a k7a8(9k0( 1 w i a1k2(3k4(5k6( 27m8N9( 20m1N5L52]
[DELETED: ( Nw i a k a M o 3m( 2m w i a k a 2 o2( 2w( 2 [0y1( 22y3( N t4b w i a k a 25N6( 17w i a k a b o b8d9(0i1(2(3(4a5( 6 w i a6k7( 2 w i a k a 2 58d9(0( 2 w i a1k5L52]
[DELETED: ((4(( 3 w i a k aM( 3 w i a ka(0( n 4 w1i2(3q4i a s o s n i t s t i5s d f 2 w i a6k7w8i9a t a p w a a g o w o n f0s o t i r t a e w a a a1h2( 5 w i a k a 53D4(5D6(7H8( 4 w i a k a 49H0(155L52]
[DELETED: (D( 5 w i a k a 5M(D(( A s c a q o t fm0(1(2(3(4(5(6( B o b o7b8(9a0b t i s d b a m f 21a2n o t r s w o n t c i3f4( S i t r s t a e w a5a a h h o h s6w o n f s i t r s b o o m7o8( S a t 3 w a a a9s0( S a t 2 n a w a o1d5L52]
[DELETED: s( U s e o u l i asati w t e o s s i a s oi( A 7y a i i s i a s o0i1(2(3(4h 4 4 A S5O6( U s e o u l i a7s8a9c n s i i s i a s o0i1(2(3( A a 2 o 44d5( C 2 a6a7(8i S o n 2 a9( 2 a0N m m1e5L52]
[DELETED: ( ( a (p( N Na(( 4 ( n 4 4m( N - pi i i s i a s o0i1( A c s a t t e i f2h3S4( A o t f s e t n d5l i o s w p d o i b6e7c s o b c o e a c8s9( O a o a a s c d o0p o o o o e a b1t b d n n2n3(4(5(6(7(8(9(0(1(5L52]
[DELETED: (((((((((0(1c2t3s4(5(6o c l a a s c d o p7t8s9a s o o i e t t s s n0i d c l o e w d n c1c2(3e l s o p f w c t p4a5(6o7a8s9c0(1(5L52]
[DELETED: ((((((((( M 40b1( M 22d3(4(5(6(7( P e8c9( P 10c1(2(3(4(5(6(7(8(9( L w i a k a l0a1(5L52]
[DELETED: ((((a q o t f s h a p f aa( A i s o i a s o io(0(1(2(3(4a q o t f s h a p f a5a w a d e o t c n s6i t s i a s o i w t7e8t9(0(1(2(3(4(5( N A n f n (6d 67d8(9f0( U s e o u l i a1s5L52]
[DELETED: a( I p t a a mPt P P b m k a m bk((((0(1S2(3a q o t f s h a p f a4a w a s e o t c n s5i6a7a s o i i p w t s c8d9(0(1(2(3(4a q o t f s h a p f a5a6( A s w c a q o a d o7b8t9s0(1(5L52]
[DELETED: (((((((((0(1(2(3(4(5(6(7(8(9( A c m o p c a0s1a2( A s d f c a3s p o a s o a o t d a4a5a6( A d p c g a7i i s i a s o i f w a8a9C0(1n f k (5L52]
[DELETED: c( T a z o a s t T o onai b a n l t 2cn l t 4t( U s e o u l i a0s1( A m c m o p c2l3c4a5( N m t o a e g o c p o6h7w8( N m t o a e g o c p o9h0w o o m a n i i r1t2(3o h m o n m t n m p d4u w o o m a n i i r5t6(7h8w o o m a n i i r9t0(1m o p o h g o n m t t5L52]
[DELETED: m p d u w o o m a ni( N m t f m o m p o hmi(o((0D E A o t U S D o1J2w s i a m c m o p3c4i a s o i w t e o s s o5i6(7(8(9( 1 (0e1( 1 (2e3(4(5(6(7(8( B (9h0(1(5L52]
[DELETED: (e(( D (a( D (e( D ( 'h0(1( D (2a3(4( F (5d6( F ( (7a8( F (9f0(1(2( 4 (3o4( M (5o6( M (7o8( M (9d0(1e5L52]
[DELETED: ( M (b( M (o(((( 1 (h0( M (1d2( M (3t4( M (5e6( M (7e8( 1 (9h ( '0m1(2(3(4(5(6( 1 (7d8(9(0( N ( 11e5L52]
[DELETED: (( N (o( N (o( O (a( O (e0( O (1h2( P (3c4( S (5a6( S (7o8( T (9o0(1( T ( 12h3(4(5(6(7(8(9(0(1(5L52]
[DELETED: ( 2 a 3 a a ab(( 4 a bd((((0(1(2(3(4(5(6l7g8(9(0g1A S o n f d a (2t3(4S5(6a7a8s9(0(1(5L52]
[DELETED: ( C b n i l (h a c b o m ( aw((((((0(1(2(3(4(5(6(7(8(9(0(1(2(3(4(5(6(7(8(9(0(1(5L52]
[DELETED: (((((((((0(1(2(3(4(5(6(7(8(9(0(1(2(3(4(5(6(7(8(9(0(1(5L52]
[DELETED: a q o t f s i i s iw o p o g a s o s iwp( U s e o u l i asacp0o s s i a s o i i p w t1s2(3(4( P i o c a c5t6(7(8(9(0(1(2(3(4(5( U s e o u l i a6s7a8c9a0(1( N m t o m o d a n l t5L52]
[DELETED: t( 2 is o a g i a s o t i ti( U s e o u l i asas(0(1(2a3i4i5( U s e o u l i a6s7a q o t f s i i s o8i9( T f d p c e i s0o i a s o s o i a e f1s ( o S I i t ( a s b 2c3t a c n a f a e t a t d4p5c6o7p r o o a m t t a s8g o e b d a t p n c9s p r o o a m t n g o0e1a5L52]
[DELETED: cpm c w t p O T F o FMu(ih(0(1S2( A c m o p c a o t3f4f a b o a w s i o o m5n a m i i s p t6c u t c m o p v m7q8(9m0(1h2( N m t o h m o e p o3h4( N m t t a f m o d5a6u7(8m9( N m t f m o d a n l0t1( U s e o e o u l i5L52]
[DELETED: ac a q o t f s h a ses( U s e o e o u l iac a q o t f s h a des0( E (1a2(3(4(5( B (6b7s8(9(0S 2  O s 2 R S C1S5L52]